STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 169397

TO: Bao-Qun Li **Art Unit:** 1648 **Location:** REM 3C18/3D24 **Serial Number:** 09/718803 **Wednesday, May 10, 2006**	**From:** Beverly Shears **Location:** Biotech-Chem Library REM 1A54 **Phone:** 571-272-2528 beverly.shears@uspto.gov

Search Notes

Bao-Qun,

Attached pls. find RAG result file for Seq. ID 2. A total of 1000 Summary Table hits and 100 alignments are displayed. I have resubmitted the query to display the top 350 alignments; however, the results will not be avail. until tomorrow a.m., May 11th. I will forward those results ASAP.

You may access an electronic version via eDAN (SCORE) and /or http://es/ScoreAccessWeb. If the results have been separated into two (2) or more versions, you may view additional files via the select "View version list for this application" link.

Beverly

THIS PAGE LEFT BLANK

189397

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

SEARCH REQUEST FORM

Requestor's Name: Li, B (78206) Serial Number: 09/718803

Date: 05-09-06 Phone: _____ Art Unit: 1648

REM3C18/3D24

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevent citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevent claim(s).

Seq ID 2, File RAG

Longer hit / align. listing

5/10

350

STAFF USE ONLY

Date completed: _____

Searcher: Beverly e2528

Terminal time: _____

Elapsed time: _____

CPU time: _____

Total time: _____

Number of Searches: _____

Number of Databases: _____

Search Site

_____ STIC

_____ CM-1

_____ Pre-S

Type of Search

_____ N.A. Sequence

_____ A.A. Sequence

_____ Structure

_____ Bibliographic

Vendors

_____ IG

_____ STN

_____ Dialog

_____ APS

_____ Geninfo

_____ SDC

_____ DARC/Questel

✓ Other CGN

THIS PAGE LEFT BLANK

GenCore version 5.1.8

OM protein - protein search, using sw model

Run on: May 9, 2006, 15:20:27 ; Search time 80 Seconds
(without alignments)
642.591 Million cell updates/sec

Title: US-09-718-803A-2
Perfect score: 611
Sequence: 1 MPSPGTVCSLLLLGMLWLDL.....LGKFLQDILWEEAKEAPADK 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : A_Geneseq_21:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
9: geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	611	100.0	117	2	AAW87991	Aaw87991 Protein d
2	611	100.0	117	3	AAY87236	Aay87236 Human sig
3	611	100.0	117	4	AAB20101	Aab20101 Zsig33 pr
4	611	100.0	117	4	AAB62649	Aab62649 Human zsi
5	611	100.0	117	4	AAM38890	Aam38890 Human pol
6	611	100.0	117	4	AAB60511	Aab60511 Human ghr
7	611	100.0	117	5	ABB78319	Abb78319 Amino aci
8	611	100.0	117	5	AAE23838	Aae23838 Human zsi
9	611	100.0	117	5	AAE15883	Aae15883 Human zsi
10	611	100.0	117	6	ABU58046	Abu58046 Human PRO
11	611	100.0	117	6	ABU59124	Abu59124 Novel hum
12	611	100.0	117	6	ABU82636	Abu82636 Human sec
13	611	100.0	117	6	ABO17836	Abo17836 Novel hum
14	611	100.0	117	6	ABU60555	Abu60555 Human sec
15	611	100.0	117	6	ABU13937	Abu13937 Human PRO
16	611	100.0	117	6	ABU81090	Abu81090 Human PRO
17	611	100.0	117	6	ABU72522	Abu72522 Novel hum
18	611	100.0	117	6	ABU66790	Abu66790 Human PRO
19	611	100.0	117	6	ABU59871	Abu59871 Novel sec
20	611	100.0	117	6	ABU59271	Abu59271 Human sec
21	611	100.0	117	6	ABO25968	Abo25968 Human PRO
22	611	100.0	117	6	ABO25061	Abo25061 Human sec
23	611	100.0	117	6	ABU58977	Abu58977 Human sec
24	611	100.0	117	6	ABU92355	Abu92355 Novel hum
25	611	100.0	117	6	AAE33409	Aae33409 Human pre
26	611	100.0	117	6	ABU59420	Abu59420 Novel hum
27	611	100.0	117	6	ABU67066	Abu67066 Human sec
28	611	100.0	117	6	ABU92186	Abu92186 Novel hum
29	611	100.0	117	6	ABU10892	Abu10892 Human PRO
30	611	100.0	117	6	ABU81644	Abu81644 Novel hum
31	611	100.0	117	6	ABU88583	Abu88583 Human sec
32	611	100.0	117	6	ABO34097	Abo34097 Human PRO
33	611	100.0	117	6	ADA45961	Ada45961 Novel hum
34	611	100.0	117	6	ADA76392	Ada76392 Human PRO
35	611	100.0	117	6	ADA19042	Ada19042 Human PRO
36	611	100.0	117	6	ADA61665	Ada61665 Homo sapi
37	611	100.0	117	6	ADB19450	Adb19450 Novel hum
38	611	100.0	117	6	ADB27991	Adb27991 Human PRO
39	611	100.0	117	6	ADA86470	Ada86470 Novel hum
40	611	100.0	117	6	ADB16034	Adb16034 Human PRO
41	611	100.0	117	6	ADA37779	Ada37779 Human sec
42	611	100.0	117	6	ADA47820	Ada47820 Human PRO
43	611	100.0	117	6	ADA21465	Ada21465 Human sec
44	611	100.0	117	6	ADA10252	Ada10252 Human sec
45	611	100.0	117	6	ADA67615	Ada67615 Human PRO
46	611	100.0	117	6	ADB30622	Adb30622 Human PRO
47	611	100.0	117	6	ADA85918	Ada85918 Novel hum
48	611	100.0	117	6	ADA17796	Ada17796 Human PRO
49	611	100.0	117	6	ADA97130	Ada97130 Human PRO
50	611	100.0	117	6	ADA79434	Ada79434 Human PRO
51	611	100.0	117	6	ADA87573	Ada87573 Novel hum
52	611	100.0	117	6	ADB16775	Adb16775 Human PRO
53	611	100.0	117	6	ADA27904	Ada27904 Human sec
54	611	100.0	117	6	ADA91867	Ada91867 Novel hum
55	611	100.0	117	6	ADB14930	Adb14930 Human PRO
56	611	100.0	117	6	ADB18891	Adb18891 Novel hum
57	611	100.0	117	6	ADA94106	Ada94106 Human PRO
58	611	100.0	117	6	ADB20002	Adb20002 Novel hum
59	611	100.0	117	6	ADB13314	Adb13314 Human PRO
60	611	100.0	117	6	ABO43369	Abo43369 Novel hum
61	611	100.0	117	6	ADA94484	Ada94484 Human sec
62	611	100.0	117	6	ADA74568	Ada74568 Human PRO
63	611	100.0	117	6	ADB24801	Adb24801 Human PRO
64	611	100.0	117	6	ADA82325	Ada82325 Human PRO
65	611	100.0	117	6	ADA75288	Ada75288 Human PRO
66	611	100.0	117	6	ADA85366	Ada85366 Novel hum
67	611	100.0	117	6	ADA84814	Ada84814 Novel hum
68	611	100.0	117	6	ADB30070	Adb30070 Human PRO
69	611	100.0	117	6	ADA80598	Ada80598 Human PRO
70	611	100.0	117	6	ADA75840	Ada75840 Human PRO
71	611	100.0	117	6	ADA38709	Ada38709 Human sec
72	611	100.0	117	6	ADA47065	Ada47065 Human PRO
73	611	100.0	117	6	ADB25361	Adb25361 Human PRO
74	611	100.0	117	6	ADA93537	Ada93537 Human PRO
75	611	100.0	117	6	ADB26887	Adb26887 Human PRO
76	611	100.0	117	6	ADB31174	Adb31174 Human PRO
77	611	100.0	117	6	ADA92830	Ada92830 Human sec
78	611	100.0	117	6	ADA61102	Ada61102 Homo sapi
79	611	100.0	117	6	ADB24249	Adb24249 Human PRO
80	611	100.0	117	6	ADA96578	Ada96578 Human PRO
81	611	100.0	117	6	ADA81150	Ada81150 Human PRO
82	611	100.0	117	6	ADA96026	Ada96026 Human PRO
83	611	100.0	117	6	ADB26335	Adb26335 Human PRO
84	611	100.0	117	6	ADB21820	Adb21820 Novel hum
85	611	100.0	117	7	ADA77599	Ada77599 Human PRO
86	611	100.0	117	7	ADB18339	Adb18339 Human PRO
87	611	100.0	117	7	ADA87022	Ada87022 Novel hum
88	611	100.0	117	7	ADA88125	Ada88125 Novel hum
89	611	100.0	117	7	ADA46513	Ada46513 Novel hum
90	611	100.0	117	7	ADB28543	Adb28543 Human PRO
91	611	100.0	117	7	ADB29095	Adb29095 Human PRO
92	611	100.0	117	7	ABO53183	Abo53183 Human sec
93	611	100.0	117	7	ADA77047	Ada77047 Human PRO
94	611	100.0	117	7	ADA22391	Ada22391 Human sec
95	611	100.0	117	7	ADA88677	Ada88677 Novel hum
96	611	100.0	117	7	ADA97682	Ada97682 Human PRO
97	611	100.0	117	7	ADB27439	Adb27439 Human PRO

98	611	100.0	117	7	ADB22372	Adb22372	Novel hum
99	611	100.0	117	7	ABO22553	Abo22553	Human sec
100	611	100.0	117	7	ADA06557	Ada06557	Human sec
101	611	100.0	117	7	ADA39250	Ada39250	Human sec
102	611	100.0	117	7	ADA67063	Ada67063	Human PRO
103	611	100.0	117	7	ADB22924	Adb22924	Human PRO
104	611	100.0	117	7	ADB23697	Adb23697	Human PRO
105	611	100.0	117	7	ADA92419	Ada92419	Novel hum
106	611	100.0	117	7	ADB15482	Adb15482	Human PRO
107	611	100.0	117	7	ADB38734	Adb38734	Novel hum
108	611	100.0	117	7	ADB96276	Adb96276	Human PRO
109	611	100.0	117	7	ADB38182	Adb38182	Novel hum
110	611	100.0	117	7	ADB66654	Adb66654	Novel hum
111	611	100.0	117	7	ADB89734	Adb89734	Human PRO
112	611	100.0	117	7	ADB90466	Adb90466	Human PRO
113	611	100.0	117	7	ADB39567	Adb39567	Novel hum
114	611	100.0	117	7	ADB47190	Adb47190	Novel hum
115	611	100.0	117	7	ADB86797	Adb86797	Human PRO
116	611	100.0	117	7	ADB77402	Adb77402	Novel hum
117	611	100.0	117	7	ADB34559	Adb34559	Human PRO
118	611	100.0	117	7	ADB35663	Adb35663	Human PRO
119	611	100.0	117	7	ADB34007	Adb34007	Human PRO
120	611	100.0	117	7	ADB35111	Adb35111	Human PRO
121	611	100.0	117	7	ADB36215	Adb36215	Human PRO
122	611	100.0	117	7	ADB46610	Adb46610	Novel hum
123	611	100.0	117	7	ADC57748	Adc57748	Human PRO
124	611	100.0	117	7	ADC55112	Adc55112	Human PRO
125	611	100.0	117	7	ADC11979	Adc11979	Human sec
126	611	100.0	117	7	ADC56401	Adc56401	Human PRO
127	611	100.0	117	7	ADC07456	Adc07456	Human sec
128	611	100.0	117	7	ADC11446	Adc11446	Human sec
129	611	100.0	117	7	ADC50483	Adc50483	Novel hum
130	611	100.0	117	7	ADC72030	Adc72030	Novel hum
131	611	100.0	117	7	ADC60009	Adc60009	Novel hum
132	611	100.0	117	7	ADC53016	Adc53016	Novel hum
133	611	100.0	117	7	ADC57370	Adc57370	Novel hum
134	611	100.0	117	7	ADC60561	Adc60561	Novel hum
135	611	100.0	117	7	ADC51036	Adc51036	Novel hum
136	611	100.0	117	7	ADC65563	Adc65563	Human PRO
137	611	100.0	117	7	ADC54661	Adc54661	Novel hum
138	611	100.0	117	7	ADC53622	Adc53622	Novel hum
139	611	100.0	117	7	ADC59145	Adc59145	Novel hum
140	611	100.0	117	7	ADC56023	Adc56023	Novel hum
141	611	100.0	117	7	ADC58593	Adc58593	Novel hum
142	611	100.0	117	7	ADC14568	Adc14568	Novel hum
143	611	100.0	117	7	ADD08100	Add08100	Novel hum
144	611	100.0	117	7	ADD03267	Add03267	Novel hum
145	611	100.0	117	7	ADC90259	Adc90259	Novel hum
146	611	100.0	117	7	ADC81925	Adc81925	Human PRO
147	611	100.0	117	7	ADC69678	Adc69678	Human PRO
148	611	100.0	117	7	ADC48567	Adc48567	Human PRO
149	611	100.0	117	7	ADD10096	Add10096	Human PRO
150	611	100.0	117	7	ADD07567	Add07567	Novel hum
151	611	100.0	117	7	ADD04671	Add04671	Novel hum
152	611	100.0	117	7	ADC82458	Adc82458	Human PRO
153	611	100.0	117	7	ADC80627	Adc80627	Novel hum
154	611	100.0	117	7	ADD11134	Add11134	Human PRO
155	611	100.0	117	7	ADC48015	Adc48015	Human PRO
156	611	100.0	117	7	ADD08638	Add08638	Novel hum
157	611	100.0	117	7	ADC80075	Adc80075	Novel hum
158	611	100.0	117	7	ADD06887	Add06887	Novel hum
159	611	100.0	117	7	ADD09544	Add09544	Human PRO
160	611	100.0	117	7	ADC83134	Adc83134	Human PRO
161	611	100.0	117	7	ADD41257	Add41257	Novel hum
162	611	100.0	117	7	ADD52396	Add52396	Human PRO
163	611	100.0	117	7	ADD53136	Add53136	Human PRO
164	611	100.0	117	7	ADD53688	Add53688	Novel hum
165	611	100.0	117	7	ADD55241	Add55241	Human PRO
166	611	100.0	117	7	ADD56199	Add56199	Human PRO
167	611	100.0	117	7	ADD51844	Add51844	Human PRO
168	611	100.0	117	7	ADD02643	Add02643	Human PRO
169	611	100.0	117	7	ADD02077	Add02077	Human PRO
170	611	100.0	117	7	ADD54259	Add54259	Novel hum
171	611	100.0	117	7	ADD54637	Add54637	Human PRO
172	611	100.0	117	7	ADD92576	Add92576	Human PRO
173	611	100.0	117	7	ADD91472	Add91472	Human PRO
174	611	100.0	117	7	ADE04086	Ade04086	Human PRO
175	611	100.0	117	7	ADE26791	Ade26791	Novel hum
176	611	100.0	117	7	ADE32383	Ade32383	Novel hum
177	611	100.0	117	7	ADE22315	Ade22315	Human PRO
178	611	100.0	117	7	ADD79539	Add79539	Human PRO
179	611	100.0	117	7	ADE42075	Ade42075	Human PRO
180	611	100.0	117	7	ADE17892	Ade17892	Human PRO
181	611	100.0	117	7	ADD92024	Add92024	Human PRO
182	611	100.0	117	7	ADE33487	Ade33487	Novel hum
183	611	100.0	117	7	ADE34039	Ade34039	Novel hum
184	611	100.0	117	7	ADD80091	Add80091	Human PRO
185	611	100.0	117	7	ADD93128	Add93128	Human PRO
186	611	100.0	117	7	ADE19548	Ade19548	Human PRO
187	611	100.0	117	7	ADE18996	Ade18996	Human PRO
188	611	100.0	117	7	ADE43192	Ade43192	Human PRO
189	611	100.0	117	7	ADD95981	Add95981	Human PRO
190	611	100.0	117	7	ADE22867	Ade22867	Human PRO
191	611	100.0	117	7	ADD78985	Add78985	Human PRO
192	611	100.0	117	7	ADE26258	Ade26258	Novel hum
193	611	100.0	117	7	ADE32935	Ade32935	Novel hum
194	611	100.0	117	7	ADE42627	Ade42627	Human PRO
195	611	100.0	117	7	ADD80643	Add80643	Human PRO
196	611	100.0	117	7	ADD89671	Add89671	Human PRO
197	611	100.0	117	7	ADE40955	Ade40955	Human PRO
198	611	100.0	117	7	ADE04754	Ade04754	Human PRO
199	611	100.0	117	7	ADE92883	Ade92883	Human PRO
200	611	100.0	117	7	ADF67195	Adf67195	Human PRO
201	611	100.0	117	7	ADG21592	Adg21592	Novel hum
202	611	100.0	117	7	ADG23233	Adg23233	Novel hum
203	611	100.0	117	7	ADF97568	Adf97568	Human PRO
204	611	100.0	117	7	ADG80632	Adg80632	Human PRO
205	611	100.0	117	7	ADG80080	Adg80080	Human PRO
206	611	100.0	117	7	ADH55372	Adh55372	Novel hum
207	611	100.0	117	7	ADH55924	Adh55924	Novel hum
208	611	100.0	117	7	ADI35449	Adi35449	Human PRO
209	611	100.0	117	7	ADI33328	Adi33328	Motilin h
210	611	100.0	117	7	ADI64143	Adi64143	Novel hum
211	611	100.0	117	7	ADI63591	Adi63591	Novel hum
212	611	100.0	117	7	ADH82005	Adh82005	Novel hum
213	611	100.0	117	7	ADH99941	Adh99941	Novel hum
214	611	100.0	117	7	ADH81453	Adh81453	Novel hum
215	611	100.0	117	7	ADM82622	Adm82622	Novel hum
216	611	100.0	117	7	ADN16021	Adn16021	Novel hum
217	611	100.0	117	7	ADN16650	Adn16650	Novel hum
218	611	100.0	117	7	ADN15469	Adn15469	Novel hum
219	611	100.0	117	7	ADN14917	Adn14917	Novel hum
220	611	100.0	117	7	ADI65092	Adi65092	Novel hum
221	611	100.0	117	8	ADC81179	Adc81179	Novel hum
222	611	100.0	117	8	ADD76627	Add76627	Human PRO
223	611	100.0	117	8	ADD87991	Add87991	Human PRO
224	611	100.0	117	8	ADD86395	Add86395	Human PRO
225	611	100.0	117	8	ADE75843	Ade75843	Human PRO
226	611	100.0	117	8	ADE23419	Ade23419	Human PRO
227	611	100.0	117	8	ADE23971	Ade23971	Human PRO
228	611	100.0	117	8	ADE24614	Ade24614	Human PRO
229	611	100.0	117	8	ADD87439	Add87439	Human PRO
230	611	100.0	117	8	ADE89305	Ade89305	Human PRO
231	611	100.0	117	8	ADE18444	Ade18444	Human PRO
232	611	100.0	117	8	ADE88753	Ade88753	Human PRO
233	611	100.0	117	8	ADE94773	Ade94773	Human PRO
234	611	100.0	117	8	ADE91184	Ade91184	Human PRO
235	611	100.0	117	8	ADF35394	Adf35394	Human PRO
236	611	100.0	117	8	ADE95325	Ade95325	Human PRO
237	611	100.0	117	8	ADE93435	Ade93435	Human PRO
238	611	100.0	117	8	ADF35016	Adf35016	Human PRO
239	611	100.0	117	8	ADE92331	Ade92331	Novel hum
240	611	100.0	117	8	ADE90632	Ade90632	Human PRO
241	611	100.0	117	8	ADE91779	Ade91779	Novel hum
242	611	100.0	117	8	ADG11644	Adg11644	Human PRO
243	611	100.0	117	8	ADG02358	Adg02358	Human PRO

244	611	100.0	117	8	ADG22144	Adg22144	Novel hum
245	611	100.0	117	8	ADG20214	Adg20214	Human PRO
246	611	100.0	117	8	ADF98120	Adf98120	Human PRO
247	611	100.0	117	8	ADG24337	Adg24337	Novel hum
248	611	100.0	117	8	ADF98691	Adf98691	Human PRO
249	611	100.0	117	8	ADG03522	Adg03522	Human PRO
250	611	100.0	117	8	ADF99243	Adf99243	Human PRO
251	611	100.0	117	8	ADG16828	Adg16828	Human PRO
252	611	100.0	117	8	ADG05287	Adg05287	Human PRO
253	611	100.0	117	8	ADG19554	Adg19554	Human PRO
254	611	100.0	117	8	ADG13391	Adg13391	Human PRO
255	611	100.0	117	8	ADG08448	Adg08448	Novel hum
256	611	100.0	117	8	ADG15618	Adg15618	Human PRO
257	611	100.0	117	8	ADF97016	Adf97016	Human PRO
258	611	100.0	117	8	ADG06201	Adg06201	Human PRO
259	611	100.0	117	8	ADG23785	Adg23785	Novel hum
260	611	100.0	117	8	ADG04074	Adg04074	Human PRO
261	611	100.0	117	8	ADG24975	Adg24975	Novel hum
262	611	100.0	117	8	ADG07272	Adg07272	Novel hum
263	611	100.0	117	8	ADG07824	Adg07824	Novel hum
264	611	100.0	117	8	ADG55319	Adg55319	Novel hum
265	611	100.0	117	8	ADG60983	Adg60983	Novel hum
266	611	100.0	117	8	ADG62087	Adg62087	Novel hum
267	611	100.0	117	8	ADG82288	Adg82288	Human PRO
268	611	100.0	117	8	ADG57527	Adg57527	Novel hum
269	611	100.0	117	8	ADG56975	Adg56975	Novel hum
270	611	100.0	117	8	ADG55871	Adg55871	Novel hum
271	611	100.0	117	8	ADG58631	Adg58631	Novel hum
272	611	100.0	117	8	ADG70997	Adg70997	Novel hum
273	611	100.0	117	8	ADG58079	Adg58079	Novel hum
274	611	100.0	117	8	ADG53663	Adg53663	Novel hum
275	611	100.0	117	8	ADG71549	Adg71549	Novel hum
276	611	100.0	117	8	ADG81736	Adg81736	Human PRO
277	611	100.0	117	8	ADH19514	Adh19514	Human sec
278	611	100.0	117	8	ADH30698	Adh30698	Human PRO
279	611	100.0	117	8	ADH12065	Adh12065	Novel hum
280	611	100.0	117	8	ADG52487	Adg52487	Novel hum
281	611	100.0	117	8	ADG54215	Adg54215	Novel hum
282	611	100.0	117	8	ADG81184	Adg81184	Human PRO
283	611	100.0	117	8	ADG56423	Adg56423	Novel hum
284	611	100.0	117	8	ADH12689	Adh12689	Novel hum
285	611	100.0	117	8	ADH21007	Adh21007	Human sec
286	611	100.0	117	8	ADG61535	Adg61535	Novel hum
287	611	100.0	117	8	ADH20047	Adh20047	Human sec
288	611	100.0	117	8	ADH28622	Adh28622	Human PRO
289	611	100.0	117	8	ADG54767	Adg54767	Novel hum
290	611	100.0	117	8	ADG59807	Adg59807	Novel hum
291	611	100.0	117	8	ADI81231	Adi81231	Human PRO
292	611	100.0	117	8	ADG09974	Adg09974	Novel hum
293	611	100.0	117	8	ADI15445	Adi15445	Novel hum
294	611	100.0	117	8	ADG09322	Adg09322	Novel hum
295	611	100.0	117	8	ADI14777	Adi14777	Novel hum
296	611	100.0	117	8	ADI18372	Adi18372	Novel hum
297	611	100.0	117	8	ADJ67284	Adj67284	Human ghr
298	611	100.0	117	8	ADJ63653	Adj63653	Novel hum
299	611	100.0	117	8	ADJ77548	Adj77548	Human PRO
300	611	100.0	117	8	ADJ65670	Adj65670	Human PRO
301	611	100.0	117	8	ADM27806	Adm27806	Human PRO
302	611	100.0	117	8	ADM06907	Adm06907	Human ghr
303	611	100.0	117	8	ADM42530	Adm42530	Human PRO
304	611	100.0	117	8	ADN11753	Adn11753	Human zsi
305	611	100.0	117	8	ADM28392	Adm28392	Human PRO
306	611	100.0	117	8	ADI95874	Adi95874	Human PRO
307	611	100.0	117	8	ADI96426	Adi96426	Novel hum
308	611	100.0	117	8	ADQ39730	Adq39730	Human myo
309	611	100.0	117	8	ADS32378	Ads32378	Novel hum
310	611	100.0	117	8	ADT03362	Adt03362	Human PRO
311	611	100.0	117	9	ADY39261	Ady39261	Human zsi
312	611	100.0	117	9	ADY78073	Ady78073	Human ghr
313	611	100.0	117	9	ADY72885	Ady72885	Human ghr
314	611	100.0	117	9	ADZ03413	Adz03413	Human sec
315	611	100.0	117	9	ADZ64763	Adz64763	Human ghr
316	611	100.0	117	9	AEB14159	Aeb14159	Cancer ce
317	611	100.0	117	9	AEC21076	Aec21076	Virus-lik
318	611	100.0	118	3	AAY66708	Aay66708	Membrane-
319	611	100.0	118	4	AAU12392	Aau12392	Human PRO
320	611	100.0	118	4	AAB65231	Aab65231	Human PRO
321	611	100.0	118	9	AEA38521	Aea38521	Human sec
322	611	100.0	126	4	AAM40676	Aam40676	Human pol
323	611	100.0	160	8	ADQ39729	Adq39729	Human myo
324	605	99.0	117	8	ADJ67285	Adj67285	Dog ghrel
325	605	99.0	117	9	AEC21077	Aec21077	Virus-lik
326	604	98.9	117	8	ADJ67286	Adj67286	Mouse ghr
327	604	98.9	117	9	AEC21078	Aec21078	Virus-lik
328	595.5	97.5	116	4	AAB60517	Aab60517	Human des
329	524	85.8	117	8	ADM06906	Adm06906	Mouse ghr
330	518	84.8	117	4	AAB60510	Aab60510	Rat ghrel
331	518	84.8	117	8	ADM06905	Adm06905	Rat ghrel
332	502.5	82.2	116	4	AAB60516	Aab60516	Rat des-G
333	476	77.9	117	8	ADM06908	Adm06908	Canine gh
334	472.5	77.3	118	4	AAB60520	Aab60520	Porcine g
335	472.5	77.3	118	8	ADM06909	Adm06909	Porcine g
336	457	74.8	117	4	AAB60521	Aab60521	Porcine d
337	417.5	68.3	116	8	ADM06910	Adm06910	Bovine gh
338	392	64.2	90	5	ABP08975	Abp08975	Human ORF
339	392	64.2	91	6	AAE33410	Aae33410	Human exo
340	315.5	51.6	89	4	AAB60523	Aab60523	Bovine gh
341	315	51.6	60	8	ADK66754	Adk66754	Human ghr
342	296	48.4	57	8	ADK66759	Adk66759	Human ghr
343	269	44.0	60	8	ADK66752	Adk66752	Mouse ghr
344	255	41.7	57	8	ADK66757	Adk66757	Mouse ghr
345	243.5	39.9	61	8	ADK66756	Adk66756	Porcine g
346	243.5	39.9	61	8	ADK66755	Adk66755	Porcine g
347	229	37.5	57	8	ADK66760	Adk66760	Porcine g
348	229	37.5	57	8	ADK66761	Adk66761	Porcine g
349	219	35.8	57	8	ADK66758	Adk66758	Bovine gh
350	201.5	33.0	59	8	ADK66753	Adk66753	Bovine gh
351	198	32.4	116	9	ADY78074	Ady78074	Human ghr
352	147	24.1	41	8	ADM06888	Adm06888	PADRE-con
353	146	23.9	64	8	ADM06902	Adm06902	Mature ra
354	146	23.9	68	8	ADM06904	Adm06904	Mature gh
355	146	23.9	108	4	AAB60531	Aab60531	Eel ghrel
356	145	23.7	28	4	AAB60509	Aab60509	Human ghr
357	145	23.7	28	5	AAE19032	Aae19032	Human ghr
358	145	23.7	28	5	ABB09532	Abb09532	Human ghr
359	145	23.7	28	6	ABB80235	Abb80235	Unacylate
360	145	23.7	28	7	ADF17076	Adf17076	Human alb
361	145	23.7	28	8	ADF53681	Adf53681	Human ghr
362	145	23.7	28	8	ADJ67173	Adj67173	Human ghr
363	145	23.7	28	8	ADL66822	Adl66822	Human Ghr
364	145	23.7	28	8	ADN12076	Adn12076	Protein #
365	145	23.7	28	8	ADN03336	Adn03336	Exemplary
366	145	23.7	28	8	ADR42171	Adr42171	Ghrelin r
367	145	23.7	28	8	ADU61100	Adu61100	Human gro
368	145	23.7	28	9	ADV90277	Adv90277	Protease-
369	145	23.7	28	9	ADX83574	Adx83574	Human ghr
370	145	23.7	28	9	ADY80098	Ady80098	Amino aci
371	145	23.7	28	9	ADY72886	Ady72886	Human ghr
372	145	23.7	28	9	ADZ00357	Adz00357	Human ghr
373	145	23.7	28	9	ADZ20539	Adz20539	Ghrelin p
374	145	23.7	28	9	AEA00515	Aea00515	Human acy
375	145	23.7	28	9	AEA00516	Aea00516	Human ghr
376	145	23.7	28	9	AEA23453	Aea23453	Human ghr
377	145	23.7	28	9	AEC21037	Aec21037	Virus-lik
378	145	23.7	29	8	ADJ67207	Adj67207	Human ghr
379	145	23.7	29	8	ADJ67205	Adj67205	Human ghr
380	145	23.7	30	8	ADJ67261	Adj67261	Ghrelin m
381	141	23.1	28	5	AAE19033	Aae19033	Human ghr
382	141	23.1	28	5	AAE19027	Aae19027	Human ghr
383	141	23.1	28	5	AAE19028	Aae19028	Human ghr
384	141	23.1	28	5	AAE19021	Aae19021	Human ghr
385	141	23.1	28	5	AAE19029	Aae19029	Human ghr
386	141	23.1	28	5	AAE19035	Aae19035	Human ghr
387	141	23.1	28	5	AAE19036	Aae19036	Human ghr
388	141	23.1	28	5	AAE19040	Aae19040	Human ghr
389	141	23.1	28	5	AAE19034	Aae19034	Human ghr

390	141	23.1	28	5	AAE19037	Aae19037	Human ghr
391	141	23.1	28	5	AAE19038	Aae19038	Human ghr
392	141	23.1	28	5	AAE19039	Aae19039	Human ghr
393	141	23.1	28	5	AAE19030	Aae19030	Human ghr
394	141	23.1	28	5	AAE19031	Aae19031	Human ghr
395	141	23.1	28	5	AAE19041	Aae19041	Human ghr
396	140	22.9	28	9	ADY28848	Ady28848	Human ghr
397	139	22.7	28	4	AAB60530	Aab60530	Dog ghrel
398	139	22.7	28	8	ADF53689	Adf53689	Dog ghrel
399	139	22.7	28	8	ADJ67189	Adj67189	Dog ghrel
400	139	22.7	28	8	ADL66830	Adl66830	Canine Gh
401	139	22.7	28	8	ADU61109	Adu61109	Dog growt
402	139	22.7	29	8	ADJ67211	Adj67211	Dog ghrel
403	139	22.7	29	8	ADJ67213	Adj67213	Dog ghrel
404	139	22.7	30	8	ADJ67263	Adj67263	Ghrelin m
405	139	22.7	68	8	ADM06903	Adm06903	Mature gh
406	138	22.6	28	4	AAG64943	Aag64943	Neurone d
407	138	22.6	28	4	AAB60508	Aab60508	Rat ghrel
408	138	22.6	28	5	ABB09536	Abb09536	Rat ghrel
409	138	22.6	28	8	ADF53683	Adf53683	Norway ra
410	138	22.6	28	8	ADF53685	Adf53685	Murine gh
411	138	22.6	28	8	ADJ92905	Adj92905	Rat D-ghr
412	138	22.6	28	8	ADJ67174	Adj67174	Mouse ghr
413	138	22.6	28	8	ADL66824	Adl66824	Norway ra
414	138	22.6	28	8	ADL66826	Adl66826	Murine Gh
415	138	22.6	28	8	ADU61102	Adu61102	Rat growt
416	138	22.6	28	8	ADU61104	Adu61104	Mouse gro
417	138	22.6	28	9	ADX83576	Adx83576	Human ghr
418	138	22.6	28	9	AEA23456	Aea23456	Rat ghrel
419	138	22.6	28	9	AEC21038	Aec21038	Virus-lik
420	138	22.6	29	8	ADJ67217	Adj67217	Mouse ghr
421	138	22.6	29	8	ADJ67268	Adj67268	Mouse ghr
422	138	22.6	30	8	ADJ67269	Adj67269	Mouse ghr
423	138	22.6	30	8	ADJ67245	Adj67245	Ghrelc mu
424	134	21.9	28	4	AAB60560	Aab60560	Rat ghrel
425	131	21.4	25	9	ADX83581	Adx83581	Human ghr
426	130	21.3	25	5	AAE23842	Aae23842	Human zsi
427	130	21.3	25	5	AAE15887	Aae15887	Human zsi
428	130	21.3	25	9	ADY39268	Ady39268	Human zsi
429	130	21.3	28	4	AAB60518	Aab60518	Porcine g
430	130	21.3	28	8	ADF53686	Adf53686	Porcine g
431	130	21.3	28	8	ADL66827	Adl66827	Porcine G
432	130	21.3	28	8	ADU61105	Adu61105	Pig growt
433	129.5	21.2	27	4	AAB60515	Aab60515	Human des
434	129.5	21.2	27	8	ADF53682	Adf53682	Human ghr
435	129.5	21.2	27	8	ADJ67188	Adj67188	Ghrelin p
436	129.5	21.2	27	8	ADL66823	Adl66823	Human Ghr
437	129.5	21.2	27	8	ADU61101	Adu61101	Human gro
438	129.5	21.2	27	9	ADX83575	Adx83575	Human ghr
439	129.5	21.2	27	9	AEA00518	Aea00518	Human ghr
440	129.5	21.2	27	9	AEA00517	Aea00517	Human acy
441	129.5	21.2	28	8	ADJ67206	Adj67206	Human ghr
442	129.5	21.2	28	8	ADJ67204	Adj67204	Human ghr
443	129.5	21.2	29	8	ADJ67260	Adj67260	Ghrelin m
444	128	20.9	28	8	ADF53701	Adf53701	Equine gh
445	128	20.9	28	8	ADL66842	Adl66842	Equine Gh
446	128	20.9	28	8	ADU61121	Adu61121	Equine gr
447	127	20.8	41	8	ADM06889	Adm06889	PADRE-con
448	126	20.6	24	5	AAE23839	Aae23839	Human zsi
449	126	20.6	24	5	AAE15884	Aae15884	Human zsi
450	126	20.6	24	9	ADX83582	Adx83582	Human ghr
451	126	20.6	24	9	ADY39263	Ady39263	Human zsi
452	125	20.5	24	5	AAE23843	Aae23843	Human zsi
453	125	20.5	24	5	AAE15888	Aae15888	Human zsi
454	125	20.5	24	9	ADY39269	Ady39269	Human zsi
455	123.5	20.2	27	8	ADJ67190	Adj67190	Dog ghrel
456	123.5	20.2	28	8	ADJ67212	Adj67212	Dog ghrel
457	123.5	20.2	28	8	ADJ67214	Adj67214	Dog ghrel
458	123.5	20.2	29	8	ADJ67264	Adj67264	Ghrelin m
459	122.5	20.0	27	4	AAB60514	Aab60514	Rat des-G
460	122.5	20.0	27	5	ABB09537	Abb09537	Rat des-G
461	122.5	20.0	27	8	ADF53684	Adf53684	Norway ra
462	122.5	20.0	27	8	ADJ67191	Adj67191	Mouse ghr
463	122.5	20.0	27	8	ADL66825	Adl66825	Norway ra
464	122.5	20.0	27	8	ADU61103	Adu61103	Rat growt
465	122.5	20.0	28	8	ADJ67246	Adj67246	cGhrQ14 m
466	122.5	20.0	28	8	ADJ67266	Adj67266	Mouse ghr
467	122.5	20.0	29	8	ADJ67247	Adj67247	GhrQ14C m
468	122.5	20.0	29	8	ADJ67267	Adj67267	Mouse ghr
469	121.5	19.9	41	8	ADM06890	Adm06890	PADRE-con
470	121.5	19.9	41	8	ADM06891	Adm06891	PADRE-con
471	121	19.8	23	5	AAE23841	Aae23841	Human zsi
472	121	19.8	23	5	AAE23840	Aae23840	Human zsi
473	121	19.8	23	5	AAE15885	Aae15885	Human zsi
474	121	19.8	23	5	AAE15886	Aae15886	Human zsi
475	121	19.8	23	9	ADY39264	Ady39264	Human zsi
476	121	19.8	23	9	ADY39265	Ady39265	Human zsi
477	119	19.5	23	5	AAE23844	Aae23844	Human zsi
478	119	19.5	23	5	AAE15889	Aae15889	Human zsi
479	119	19.5	23	9	ADX83583	Adx83583	Human ghr
480	119	19.5	23	9	ADY39270	Ady39270	Human zsi
481	119	19.5	24	4	AAB60559	Aab60559	Rat ghrel
482	119	19.5	99	4	AAB60534	Aab60534	Rainbow t
483	115	18.8	23	5	AAE19024	Aae19024	Human ghr
484	114.5	18.7	27	4	AAB60519	Aab60519	Porcine d
485	114.5	18.7	27	8	ADU61106	Adu61106	Pig growt
486	114.5	18.7	57	8	ADL66821	Adl66821	Human Ghr
487	114	18.7	22	9	ADX83584	Adx83584	Human ghr
488	114	18.7	40	8	ADM06892	Adm06892	PADRE-con
489	112	18.3	23	4	AAB60558	Aab60558	Rat ghrel
490	111.5	18.2	57	8	ADL66820	Adl66820	Human Ghr
491	111.5	18.2	57	8	ADL66813	Adl66813	Human Ghr
492	110	18.0	21	9	ADX83585	Adx83585	Human ghr
493	110	18.0	57	8	ADL66814	Adl66814	Human Ghr
494	110	18.0	57	8	ADL66815	Adl66815	Human Ghr
495	110	18.0	57	8	ADL66816	Adl66816	Human Ghr
496	110	18.0	57	8	ADL66817	Adl66817	Human Ghr
497	110	18.0	57	8	ADL66819	Adl66819	Human Ghr
498	110	18.0	69	8	ADL66818	Adl66818	Human Ghr
499	107	17.5	22	4	AAB60557	Aab60557	Rat ghrel
500	105	17.2	20	9	ADX83586	Adx83586	Human ghr
501	103	16.9	21	4	AAB60556	Aab60556	Rat ghrel
502	101.5	16.6	27	8	ADF53687	Adf53687	Bovine gh
503	101.5	16.6	27	8	ADL66828	Adl66828	Bovine Gh
504	101.5	16.6	27	8	ADU61107	Adu61107	Bovine gr
505	101	16.5	19	9	ADX83587	Adx83587	Human ghr
506	99.5	16.3	27	4	AAB60522	Aab60522	Bovine gh
507	99.5	16.3	27	8	ADF53688	Adf53688	Ovine ghr
508	99.5	16.3	27	8	ADL66829	Adl66829	Ovine Ghr
509	99.5	16.3	27	8	ADU61108	Adu61108	Ovine gro
510	98	16.0	20	4	AAB60555	Aab60555	Rat ghrel
511	94	15.4	18	9	ADX83588	Adx83588	Human ghr
512	94	15.4	19	4	AAB60554	Aab60554	Rat ghrel
513	91	14.9	18	8	ADN11767	Adn11767	Human zsi
514	91	14.9	18	9	ADZ64764	Adz64764	Human ghr
515	91	14.9	19	4	AAB62656	Aab62656	Human zsi
516	91	14.9	19	8	ADN11768	Adn11768	Human zsi
517	91	14.9	19	9	ADZ64766	Adz64766	Human ghr
518	90.5	14.8	82	4	AAB60533	Aab60533	Rainbow t
519	90	14.7	17	5	AAE23845	Aae23845	Human zsi
520	90	14.7	17	5	AAE15890	Aae15890	Human zsi
521	90	14.7	17	9	ADY39273	Ady39273	Human zsi
522	88.5	14.5	115	1	AAP80459	Aap80459	Sequence
523	88.5	14.5	115	9	AEB56501	Aeb56501	Radiochem
524	87	14.2	17	9	ADX83589	Adx83589	Human ghr
525	87	14.2	18	4	AAB60553	Aab60553	Rat ghrel
526	87	14.2	18	5	AAE19025	Aae19025	Human ghr
527	87	14.2	18	9	ADZ64765	Adz64765	Human ghr
528	87	14.2	19	9	ADZ64767	Adz64767	Human ghr
529	87	14.2	114	4	AAB60532	Aab60532	Xenopus g
530	86	14.1	119	1	AAP91380	Aap91380	Porcine p
531	86	14.1	119	4	AAB20102	Aab20102	Pig motil
532	86	14.1	119	4	AAB62651	Aab62651	Motilin r
533	86	14.1	119	7	ADI33329	Adi33329	Pig motil
534	86	14.1	119	8	ADN11759	Adn11759	Porcine m
535	85	13.9	16	5	AAE23847	Aae23847	Human zsi

536	85	13.9	16	5	AAE23846	Aae23846	Human zsi
537	85	13.9	16	5	AAE15891	Aae15891	Human zsi
538	85	13.9	16	5	AAE15892	Aae15892	Human zsi
539	85	13.9	16	9	ADY39275	Ady39275	Human zsi
540	85	13.9	16	9	ADY39274	Ady39274	Human zsi
541	83	13.6	16	8	ADS84483	Ads84483	Ghrelin C
542	82	13.4	16	9	ADX83590	Adx83590	Human ghr
543	82	13.4	26	8	ADF53695	Adf53695	Chicken g
544	82	13.4	26	8	ADL66836	Adl66836	Chicken G
545	82	13.4	26	8	ADU61115	Adu61115	Chicken g
546	80	13.1	17	4	AAB60552	Aab60552	Rat ghrel
547	79	12.9	15	5	AAE23848	Aae23848	Human zsi
548	79	12.9	15	5	AAE15893	Aae15893	Human zsi
549	79	12.9	15	9	ADY39276	Ady39276	Human zsi
550	78.5	12.8	395	8	ADX90093	Adx90093	Plant ful
551	78.5	12.8	406	8	ADY23658	Ady23658	Plant ful
552	78	12.8	15	8	ADJ67201	Adj67201	Human ghr
553	78	12.8	15	8	ADJ67203	Adj67203	Dog ghrel
554	78	12.8	16	8	ADJ67209	Adj67209	Human ghr
555	78	12.8	24	8	ADF53694	Adf53694	Chicken g
556	78	12.8	24	8	ADL66835	Adl66835	Chicken G
557	78	12.8	24	8	ADU61114	Adu61114	Chicken g
558	77.5	12.7	344	4	ABG02123	Abg02123	Novel hum
559	77	12.6	15	9	ADX83591	Adx83591	Human ghr
560	76	12.4	15	5	AAE23852	Aae23852	Human zsi
561	76	12.4	15	5	AAE15897	Aae15897	Human zsi
562	76	12.4	15	9	ADY39284	Ady39284	Human zsi
563	76	12.4	352	9	ABM91078	Abm91078	M. xanthu
564	75.5	12.4	410	8	ADS29523	Ads29523	Bacterial
565	75	12.3	16	4	AAB60551	Aab60551	Rat ghrel
566	75	12.3	123	4	AAU17360	Aau17360	Novel sig
567	75	12.3	123	7	ADB94068	Adb94068	Human nov
568	74	12.1	24	4	AAB60524	Aab60524	Chicken g
569	74	12.1	24	8	ADF53693	Adf53693	Chicken g
570	74	12.1	24	8	ADL66834	Adl66834	Chicken G
571	74	12.1	24	8	ADU61113	Adu61113	Chicken g
572	73.5	12.0	919	8	ADT07172	Adt07172	Pfu mutan
573	73	11.9	14	9	ADX83592	Adx83592	Human ghr
574	73	11.9	323	2	AAW00923	Aaw00923	HaSNPV po
575	73	11.9	359	4	ABB59540	Abb59540	Drosophil
576	73	11.9	961	8	ADJ50176	Adj50176	Oil-assoc
577	73	11.9	1035	8	ADJ50326	Adj50326	Oil-assoc
578	72.5	11.9	157	8	ADM90965	Adm90965	Human pha
579	72.5	11.9	244	2	AAR99451	Aar99451	Thymidine
580	72.5	11.9	323	4	AAU02919	Aau02919	Angiotens
581	72.5	11.9	326	6	ABR41190	Abr41190	Human DIT
582	72.5	11.9	363	4	AAU02917	Aau02917	Angiotens
583	72.5	11.9	398	4	ABG22163	Abg22163	Novel hum
584	72.5	11.9	398	8	ADM87748	Adm87748	Human EST
585	72.5	11.9	442	4	AAU02918	Aau02918	Angiotens
586	72.5	11.9	482	2	AAR77531	Aar77531	Human pla
587	72.5	11.9	482	2	AAW62026	Aaw62026	Recombina
588	72.5	11.9	482	6	ABR39680	Abr39680	Human thy
589	72.5	11.9	482	7	ADB70356	Adb70356	Endotheli
590	72.5	11.9	482	7	ADF76381	Adf76381	Novel hum
591	72.5	11.9	482	8	ADJ37135	Adj37135	Human mal
592	72.5	11.9	482	8	ADJ66647	Adj66647	Thymidine
593	72.5	11.9	482	8	ADL82865	Adl82865	Human PRO
594	72.5	11.9	482	8	ADN04084	Adn04084	Antipsori
595	72.5	11.9	482	8	ADQ17775	Adq17775	Human sof
596	72.5	11.9	482	8	ADQ30544	Adq30544	Pancreas
597	72.5	11.9	482	8	ADP56046	Adp56046	Human PRO
598	72.5	11.9	482	8	ADP23773	Adp23773	PRO polyp
599	72.5	11.9	482	8	ADQ39454	Adq39454	Human myo
600	72.5	11.9	482	8	ADQ39457	Adq39457	Human myo
601	72.5	11.9	482	8	ADQ39455	Adq39455	Human myo
602	72.5	11.9	482	8	ADQ39456	Adq39456	Human myo
603	72.5	11.9	482	8	ADQ39453	Adq39453	Human myo
604	72.5	11.9	482	9	ADY19628	Ady19628	PRO polyp
605	72.5	11.9	482	9	ADZ14034	Adz14034	Human end
606	72.5	11.9	513	5	ABP41705	Abp41705	Human ova
607	72.5	11.9	517	4	AAU02976	Aau02976	Angiotens
608	72.5	11.9	773	7	ABO74446	Abo74446	Pseudomon
609	72.5	11.9	922	7	ADG17954	Adg17954	Native Pp
610	72.5	11.9	1038	4	ABG04908	Abg04908	Novel hum
611	72.5	11.9	1038	4	ABG25053	Abg25053	Novel hum
612	72.5	11.9	1286	4	ABG25629	Abg25629	Novel hum
613	72.5	11.9	1286	4	ABG25994	Abg25994	Novel hum
614	72.5	11.9	1286	4	ABG25086	Abg25086	Novel hum
615	71.5	11.7	580	4	AAU33463	Aau33463	Enterococ
616	71.5	11.7	589	4	AAU35210	Aau35210	Enterococ
617	71.5	11.7	589	6	ABU14523	Abu14523	Protein e
618	71.5	11.7	589	7	ADH87825	Adh87825	Enterococ
619	71.5	11.7	820	8	ADJ49667	Adj49667	Oil-assoc
620	71	11.6	556	3	AAB00125	Aab00125	Rb tumour
621	71	11.6	783	4	ABB71349	Abb71349	Drosophil
622	70.5	11.5	189	8	ADJ67022	Adj67022	Human sec
623	70.5	11.5	813	8	ABM84091	Abm84091	Human dia
624	70	11.5	15	4	AAB60550	Aab60550	Rat ghrel
625	70	11.5	220	2	AAW18066	Aaw18066	Human uro
626	70	11.5	220	4	AAM93496	Aam93496	Human pol
627	70	11.5	220	8	ADL31166	Adl31166	Human pro
628	70	11.5	221	7	ADE54982	Ade54982	Human Pro
629	70	11.5	822	8	ADK70556	Adk70556	Respirato
630	70	11.5	840	7	ADC00992	Adc00992	Enterohae
631	70	11.5	840	9	AEB91330	Aeb91330	Microbial
632	69.5	11.4	247	7	ABO78673	Abo78673	Pseudomon
633	69.5	11.4	341	7	ABO78581	Abo78581	Pseudomon
634	69.5	11.4	406	8	ADY05491	Ady05491	Plant ful
635	69.5	11.4	418	4	ABB59972	Abb59972	Drosophil
636	69.5	11.4	482	2	AAR20641	Aar20641	Placental
637	69.5	11.4	667	9	ABM95997	Abm95997	M. xanthu
638	69.5	11.4	702	4	ABB65859	Abb65859	Drosophil
639	69.5	11.4	1902	4	ABB65387	Abb65387	Drosophil
640	69	11.3	181	4	AAB94787	Aab94787	Human pro
641	69	11.3	194	4	ABG08111	Abg08111	Novel hum
642	69	11.3	314	4	AAM93516	Aam93516	Human pol
643	69	11.3	314	8	ADL31208	Adl31208	Human pro
644	69	11.3	406	7	ABO79356	Abo79356	Pseudomon
645	69	11.3	442	8	ADN04828	Adn04828	Antipsori
646	69	11.3	442	8	ABM81629	Abm81629	Tumour-as
647	69	11.3	442	9	ADY17408	Ady17408	PRO polyp
648	69	11.3	442	9	ADY20211	Ady20211	PRO polyp
649	69	11.3	585	5	ABP64785	Abp64785	Human pro
650	69	11.3	585	8	ADQ66038	Adq66038	Novel hum
651	69	11.3	1079	8	ADQ39272	Adq39272	Human myo
652	69	11.3	1088	3	AAY69192	Aay69192	A human m
653	69	11.3	1088	7	ADH30236	Adh30236	Human mon
654	69	11.3	1088	8	ADO00825	Ado00825	Human mon
655	69	11.3	1088	8	ADP25157	Adp25157	PRO polyp
656	69	11.3	1088	8	ADQ39273	Adq39273	Human myo
657	69	11.3	1088	8	ADQ39270	Adq39270	Human myo
658	69	11.3	1097	8	ADQ39271	Adq39271	Human myo
659	69	11.3	2265	4	AAB69072	Aab69072	Rabbit P/
660	69	11.3	2424	3	AAY78901	Aay78901	Calcium c
661	68.5	11.2	317	5	AAM52948	Aam52948	Human KIA
662	68.5	11.2	360	7	ABO68674	Abo68674	Pseudomon
663	68.5	11.2	367	6	ABR56768	Abr56768	Human sec
664	68.5	11.2	676	7	ABO75967	Abo75967	Pseudomon
665	68.5	11.2	793	3	AAB58442	Aab58442	Lung canc
666	68.5	11.2	1076	4	ABG10930	Abg10930	Novel hum
667	68.5	11.2	1307	8	ADQ39505	Adq39505	Human myo
668	68	11.1	13	9	ADX83593	Adx83593	Human ghr
669	68	11.1	14	5	AAE19022	Aae19022	Human ghr
670	68	11.1	14	5	AAE19023	Aae19023	Human ghr
671	68	11.1	74	5	ABP43527	Abp43527	Human sec
672	68	11.1	330	6	ABU49204	Abu49204	Protein e
673	68	11.1	430	9	ABM94045	Abm94045	M. xanthu
674	68	11.1	543	4	AAG67295	Aag67295	Amino aci
675	68	11.1	786	8	ADJ48624	Adj48624	Oil-assoc
676	67.5	11.0	137	7	ADM05251	Adm05251	Human pro
677	67.5	11.0	165	4	ABB64004	Abb64004	Drosophil
678	67.5	11.0	338	7	ADC31137	Adc31137	Human nov
679	67.5	11.0	577	9	ADW26689	Adw26689	Fructo-ol
680	67.5	11.0	731	4	ABB66167	Abb66167	Drosophil
681	67.5	11.0	901	7	ABO76907	Abo76907	Pseudomon

682	67.5	11.0	1589	4	AAM42025	Aam42025	Human pol
683	67.5	11.0	1727	4	AAB95554	Aab95554	Human pro
684	67.5	11.0	1873	7	ABM85417	Abm85417	Human pro
685	67.5	11.0	1878	4	AAM40239	Aam40239	Human pol
686	67	11.0	13	8	ADJ67200	Adj67200	Human ghr
687	67	11.0	14	8	ADJ67208	Adj67208	Human ghr
688	67	11.0	15	8	ADJ67262	Adj67262	Ghrelin m
689	67	11.0	192	8	ADX68073	Adx68073	Plant ful
690	67	11.0	388	6	ADA14289	Ada14289	Mutated M
691	67	11.0	396	8	ADQ97112	Adq97112	Human can
692	67	11.0	445	8	ADQ97114	Adq97114	Human can
693	67	11.0	621	7	ABM86093	Abm86093	Rice abio
694	67	11.0	699	7	ABO68327	Abo68327	Pseudomon
695	67	11.0	707	6	ADA54875	Ada54875	Human pro
696	67	11.0	874	7	ADS92508	Ads92508	B. lichen
697	67	11.0	874	8	ADG32058	Adg32058	Mutant B_
698	67	11.0	1047	8	ADG32230	Adg32230	Mutant B_
699	67	11.0	1331	4	AAM39048	Aam39048	Human pol
700	67	11.0	2212	7	ADD47765	Add47765	Rat Prote
701	66.5	10.9	195	4	AAM38660	Aam38660	Human pol
702	66.5	10.9	195	6	ADA54361	Ada54361	Human pro
703	66.5	10.9	197	4	AAU69434	Aau69434	Human pur
704	66.5	10.9	213	6	ABP75854	Abp75854	Human sec
705	66.5	10.9	268	8	ADY23758	Ady23758	Plant ful
706	66.5	10.9	343	8	ADT60944	Adt60944	Plant pol
707	66.5	10.9	350	8	ADX96719	Adx96719	Plant ful
708	66.5	10.9	385	6	ABU34843	Abu34843	Protein e
709	66.5	10.9	385	6	ABU36927	Abu36927	Protein e
710	66.5	10.9	443	7	ABO80700	Abo80700	Pseudomon
711	66.5	10.9	447	6	ABU09631	Abu09631	Human mon
712	66.5	10.9	447	6	ABR39440	Abr39440	Human GEN
713	66.5	10.9	447	6	ABU79089	Abu79089	Immunoglo
714	66.5	10.9	447	7	ADF43330	Adf43330	Superanti
715	66.5	10.9	575	5	ABB53420	Abb53420	Lactococc
716	66.5	10.9	575	8	ADS29267	Ads29267	Bacterial
717	66.5	10.9	920	6	ABP70827	Abp70827	Human C1Q
718	66.5	10.9	1016	3	AAB41524	Aab41524	Human ORF
719	66.5	10.9	1016	7	ADJ70151	Adj70151	Human hea
720	66.5	10.9	1016	8	ABM80282	Abm80282	Tumour-as
721	66.5	10.9	1016	9	ADV70240	Adv70240	Tumor-ass
722	66.5	10.9	1160	7	ADD24484	Add24484	DNA polym
723	66.5	10.9	1171	6	ABU50046	Abu50046	Protein e
724	66	10.8	14	4	AAB60549	Aab60549	Rat ghrel
725	66	10.8	134	6	ADA48470	Ada48470	Rice prot
726	66	10.8	152	4	ABG08055	Abg08055	Novel hum
727	66	10.8	159	5	ABP41127	Abp41127	Human ova
728	66	10.8	174	7	ABO69854	Abo69854	Pseudomon
729	66	10.8	203	2	AAR71361	Aar71361	Human tru
730	66	10.8	214	4	AAB59517	Aab59517	Human sec
731	66	10.8	246	8	ADM12888	Adm12888	Human mye
732	66	10.8	247	2	AAR70182	Aar70182	Human mye
733	66	10.8	247	2	AAR71360	Aar71360	Human MOG
734	66	10.8	247	2	AAW37543	Aaw37543	Human mye
735	66	10.8	247	3	AAY44236	Aay44236	Human mye
736	66	10.8	247	5	ABB81071	Abb81071	Human mye
737	66	10.8	247	8	ADQ14340	Adq14340	Human mye
738	66	10.8	247	8	ADR41721	Adr41721	Human mye
739	66	10.8	247	8	ADS14314	Ads14314	Human mye
740	66	10.8	247	9	AEB77801	Aeb77801	Human mye
741	66	10.8	388	5	ABB07681	Abb07681	MOG-Fc fu
742	66	10.8	388	6	ADA14265	Ada14265	Human imm
743	66	10.8	409	5	ABB07680	Abb07680	MOGxCD3 f
744	66	10.8	409	6	ADA14263	Ada14263	Human MOG
745	66	10.8	417	4	ABG28748	Abg28748	Novel hum
746	66	10.8	436	8	ADQ26344	Adq26344	Chromobac
747	66	10.8	498	4	ABG23519	Abg23519	Novel hum
748	66	10.8	568	8	ABO84801	Abo84801	Murine ca
749	66	10.8	582	8	ADS24467	Ads24467	Bacterial
750	66	10.8	720	5	AAE22055	Aae22055	Human Sta
751	66	10.8	722	9	AEB35334	Aeb35334	Mouse Sta
752	66	10.8	769	5	ABB57164	Abb57164	Mouse isc
753	66	10.8	769	5	AAE22054	Aae22054	Human Sta
754	66	10.8	769	5	AAE22056	Aae22056	Human pro
755	66	10.8	769	9	ADY16090	Ady16090	PRO polyp
756	66	10.8	769	9	AEB35332	Aeb35332	Human Sta
757	66	10.8	770	2	AAR82995	Aar82995	Mouse liv
758	66	10.8	770	2	AAR82993	Aar82993	Human pla
759	66	10.8	770	2	AAY03768	Aay03768	Human STA
760	66	10.8	770	4	AAB19964	Aab19964	Human sig
761	66	10.8	770	5	ABG69497	Abg69497	Human bai
762	66	10.8	770	5	AAE15174	Aae15174	Human Sta
763	66	10.8	770	7	ADD44738	Add44738	Rat Prote
764	66	10.8	770	7	ADD44740	Add44740	Human Pro
765	66	10.8	770	8	ADN04365	Adn04365	Antipsori
766	66	10.8	770	8	ADP54789	Adp54789	Human PRO
767	66	10.8	770	8	ADU04690	Adu04690	Human STA
768	66	10.8	770	9	ADY16088	Ady16088	PRO polyp
769	66	10.8	770	9	ADY19730	Ady19730	PRO polyp
770	66	10.8	770	9	ADY81415	Ady81415	Human sig
771	66	10.8	770	9	ADZ11212	Adz11212	Human STA
772	66	10.8	843	7	ABO80737	Abo80737	Pseudomon
773	66	10.8	1034	7	ABO72223	Abo72223	Pseudomon
774	66	10.8	2724	4	ABG20119	Abg20119	Novel hum
775	65.5	10.7	160	8	ADY12847	Ady12847	Plant ful
776	65.5	10.7	273	6	ABJ38683	Abj38683	Human nuc
777	65.5	10.7	306	8	ADY11597	Ady11597	Plant ful
778	65.5	10.7	350	6	ABP77721	Abp77721	N. gonorr
779	65.5	10.7	358	8	ADX95074	Adx95074	Plant ful
780	65.5	10.7	368	3	AAY74262	Aay74262	Neisseria
781	65.5	10.7	499	9	ABM94947	Abm94947	M. xanthu
782	65.5	10.7	573	6	ADB11786	Adb11786	Alloiococ
783	65.5	10.7	580	6	ADB11784	Adb11784	Alloiococ
784	65.5	10.7	603	6	ADB11782	Adb11782	Alloiococ
785	65.5	10.7	609	6	ADB11780	Adb11780	Alloiococ
786	65.5	10.7	721	8	ADM90967	Adm90967	Human pha
787	65.5	10.7	3541	5	AAU85130	Aau85130	Human mel
788	65	10.6	13	5	AAE23853	Aae23853	Human zsi
789	65	10.6	13	5	AAE15898	Aae15898	Human zsi
790	65	10.6	13	9	ADY39285	Ady39285	Human zsi
791	65	10.6	154	4	AAY72840	Aay72840	Mouse Sta
792	65	10.6	231	2	AAY39473	Aay39473	DNAX inte
793	65	10.6	231	6	ADA00762	Ada00762	Human DNA
794	65	10.6	231	8	ADH53871	Adh53871	Human DNA
795	65	10.6	366	4	ABG10892	Abg10892	Novel hum
796	65	10.6	371	5	ABB80577	Abb80577	Human sbg
797	65	10.6	405	7	ABO71580	Abo71580	Pseudomon
798	65	10.6	423	7	ABO71416	Abo71416	Pseudomon
799	65	10.6	453	4	AAM38830	Aam38830	Human pol
800	65	10.6	554	7	ADB85295	Adb85295	Rat tubul
801	65	10.6	590	7	ADE03421	Ade03421	Human imm
802	65	10.6	592	5	ABB80578	Abb80578	Human sbg
803	65	10.6	722	9	ADZ11213	Adz11213	Mouse STA
804	65	10.6	729	5	ABB05435	Abb05435	Absidia c
805	65	10.6	729	5	AAO14416	Aao14416	Absidia c
806	65	10.6	729	5	AAM48980	Aam48980	Absidia c
807	65	10.6	770	2	AAR72082	Aar72082	Mouse Sta
808	65	10.6	770	2	AAW03176	Aaw03176	Mouse STA
809	65	10.6	770	3	AAB12377	Aab12377	N-termina
810	65	10.6	770	5	AAE14652	Aae14652	Murine ST
811	65	10.6	770	6	ABU10476	Abu10476	Mouse STA
812	65	10.6	795	4	AAU35628	Aau35628	Haemophil
813	65	10.6	795	6	ABU30559	Abu30559	Protein e
814	64.5	10.6	94	5	ABP08124	Abp08124	Human ORF
815	64.5	10.6	140	4	ABG01615	Abg01615	Novel hum
816	64.5	10.6	158	8	ADX67495	Adx67495	Plant ful
817	64.5	10.6	169	6	AAO30474	Aao30474	Human TNF
818	64.5	10.6	245	4	ABB11533	Abb11533	Human UC
819	64.5	10.6	260	7	ABM85220	Abm85220	Mouse pro
820	64.5	10.6	261	4	ABG04730	Abg04730	Novel hum
821	64.5	10.6	300	8	ADT60068	Adt60068	Plant pol
822	64.5	10.6	308	8	ADY09659	Ady09659	Plant ful
823	64.5	10.6	314	7	ADE59072	Ade59072	Rat Prote
824	64.5	10.6	413	3	AAG42387	Aag42387	Arabidops
825	64.5	10.6	416	3	AAG42386	Aag42386	Arabidops
826	64.5	10.6	515	6	ABU99154	Abu99154	Novel hum
827	64.5	10.6	515	8	ADM93873	Adm93873	Human NOV

828	64.5	10.6	537	2	AAR90295	Aar90295	Protein h
829	64.5	10.6	537	2	AAW25746	Aaw25746	Arabidops
830	64.5	10.6	537	2	AAW41603	Aaw41603	Arabidops
831	64.5	10.6	537	2	AAW51347	Aaw51347	Arabidops
832	64.5	10.6	537	3	AAG42385	Aag42385	Arabidops
833	64.5	10.6	537	4	AAE08766	Aae08766	Arabidops
834	64.5	10.6	537	4	AAE08768	Aae08768	Arabidops
835	64.5	10.6	537	4	AAE08794	Aae08794	Arabidops
836	64.5	10.6	537	4	AAE08762	Aae08762	Arabidops
837	64.5	10.6	537	4	AAE08748	Aae08748	Arabidops
838	64.5	10.6	537	4	AAE08759	Aae08759	Arabidops
839	64.5	10.6	537	4	AAE08760	Aae08760	Arabidops
840	64.5	10.6	537	4	AAE08761	Aae08761	Arabidops
841	64.5	10.6	537	4	AAE08764	Aae08764	Arabidops
842	64.5	10.6	537	4	AAE08770	Aae08770	Arabidops
843	64.5	10.6	537	4	AAE08771	Aae08771	Arabidops
844	64.5	10.6	537	4	AAE08765	Aae08765	Arabidops
845	64.5	10.6	537	4	AAE08773	Aae08773	Arabidops
846	64.5	10.6	537	4	AAE08775	Aae08775	Arabidops
847	64.5	10.6	537	4	AAE08763	Aae08763	Arabidops
848	64.5	10.6	537	4	AAE08769	Aae08769	Arabidops
849	64.5	10.6	537	4	AAE08776	Aae08776	Arabidops
850	64.5	10.6	537	4	AAE08767	Aae08767	Arabidops
851	64.5	10.6	537	4	AAE14659	Aae14659	Arabidops
852	64.5	10.6	537	4	AAE14667	Aae14667	Arabidops
853	64.5	10.6	537	4	AAE14669	Aae14669	Arabidops
854	64.5	10.6	537	4	AAE14668	Aae14668	Arabidops
855	64.5	10.6	537	4	AAE10248	Aae10248	Arabidops
856	64.5	10.6	537	4	AAE10252	Aae10252	Arabidops
857	64.5	10.6	537	4	AAE10244	Aae10244	Arabidops
858	64.5	10.6	537	4	AAE10241	Aae10241	Arabidops
859	64.5	10.6	537	4	AAE10245	Aae10245	Arabidops
860	64.5	10.6	537	4	AAE10253	Aae10253	Arabidops
861	64.5	10.6	537	4	AAE10258	Aae10258	Arabidops
862	64.5	10.6	537	4	AAE10242	Aae10242	Arabidops
863	64.5	10.6	537	4	AAE10246	Aae10246	Arabidops
864	64.5	10.6	537	4	AAE10250	Aae10250	Arabidops
865	64.5	10.6	537	4	AAE10251	Aae10251	Arabidops
866	64.5	10.6	537	4	AAE10255	Aae10255	Arabidops
867	64.5	10.6	537	4	AAE10243	Aae10243	Arabidops
868	64.5	10.6	537	4	AAE10257	Aae10257	Arabidops
869	64.5	10.6	537	4	AAE10240	Aae10240	Arabidops
870	64.5	10.6	537	4	AAE10247	Aae10247	Arabidops
871	64.5	10.6	537	4	AAE10249	Aae10249	Arabidops
872	64.5	10.6	537	4	AAE10220	Aae10220	Arabidops
873	64.5	10.6	537	4	AAB86195	Aab86195	A. thalia
874	64.5	10.6	537	4	AAE13206	Aae13206	A. thalia
875	64.5	10.6	537	4	AAE13208	Aae13208	A. thalia
876	64.5	10.6	537	4	AAE13201	Aae13201	Arabidops
877	64.5	10.6	537	4	AAE13207	Aae13207	A. thalia
878	64.5	10.6	537	4	AAB72924	Aab72924	Arabidops
879	64.5	10.6	537	4	AAB72901	Aab72901	Arabidops
880	64.5	10.6	537	4	AAB72923	Aab72923	Arabidops
881	64.5	10.6	537	4	AAB72925	Aab72925	Arabidops
882	64.5	10.6	537	5	ABB92801	Abb92801	Herbicida
883	64.5	10.6	537	5	AAG78541	Aag78541	Arabidops
884	64.5	10.6	537	5	AAG78540	Aag78540	Arabidops
885	64.5	10.6	537	5	AAG78534	Aag78534	Arabidops
886	64.5	10.6	537	5	AAG78545	Aag78545	Arabidops
887	64.5	10.6	537	5	AAE26018	Aae26018	Arabidops
888	64.5	10.6	537	5	AAE26035	Aae26035	Arabidops
889	64.5	10.6	537	5	AAE26027	Aae26027	Arabidops
890	64.5	10.6	537	5	AAE26032	Aae26032	Arabidops
891	64.5	10.6	537	5	AAE26005	Aae26005	Arabidops
892	64.5	10.6	537	5	AAE26026	Aae26026	Arabidops
893	64.5	10.6	537	5	AAE26020	Aae26020	Arabidops
894	64.5	10.6	537	5	AAE26021	Aae26021	Arabidops
895	64.5	10.6	537	5	AAE26034	Aae26034	Arabidops
896	64.5	10.6	537	5	AAE26037	Aae26037	Arabidops
897	64.5	10.6	537	5	AAE26033	Aae26033	Arabidops
898	64.5	10.6	537	5	AAE26019	Aae26019	Arabidops
899	64.5	10.6	537	5	AAE26022	Aae26022	Arabidops
900	64.5	10.6	537	5	AAE26028	Aae26028	Arabidops
901	64.5	10.6	537	5	AAE26030	Aae26030	Arabidops
902	64.5	10.6	537	5	AAE26023	Aae26023	Arabidops
903	64.5	10.6	537	5	AAE26024	Aae26024	Arabidops
904	64.5	10.6	537	5	AAE26025	Aae26025	Arabidops
905	64.5	10.6	537	5	AAE26031	Aae26031	Arabidops
906	64.5	10.6	537	9	ADZ46711	Adz46711	A. thalia
907	64.5	10.6	577	6	ABU44391	Abu44391	Protein e
908	64.5	10.6	593	7	ADE08697	Ade08697	Novel pro
909	64.5	10.6	593	7	ADE03569	Ade03569	Human imm
910	64.5	10.6	694	6	ABM70336	Abm70336	Photorhab
911	64.5	10.6	946	9	ABM97618	Abm97618	M. xanthu
912	64.5	10.6	1137	4	ABB63542	Abb63542	Drosophil
913	64	10.5	97	9	AEB41445	Aeb41445	L. pneumo
914	64	10.5	111	9	AEB38156	Aeb38156	L. pneumo
915	64	10.5	143	3	AAG08389	Aag08389	Arabidops
916	64	10.5	164	3	AAG08388	Aag08388	Arabidops
917	64	10.5	183	5	ABP10009	Abp10009	Human ORF
918	64	10.5	191	9	ABM91135	Abm91135	M. xanthu
919	64	10.5	246	8	ADT58399	Adt58399	Plant pol
920	64	10.5	252	7	ABO79129	Abo79129	Pseudomon
921	64	10.5	306	8	ADY11164	Ady11164	Plant ful
922	64	10.5	368	8	ADX94030	Adx94030	Plant ful
923	64	10.5	394	7	ADJ68888	Adj68888	Human hea
924	64	10.5	406	5	ABP69379	Abp69379	Human pol
925	64	10.5	406	6	AAE33784	Aae33784	Human nuc
926	64	10.5	406	6	ADA55703	Ada55703	Human pro
927	64	10.5	406	7	ADM04368	Adm04368	Human pro
928	64	10.5	439	2	AAY36585	Aay36585	Fragment
929	64	10.5	439	6	ADA11755	Ada11755	Human nov
930	64	10.5	445	7	ABO79602	Abo79602	Pseudomon
931	64	10.5	472	9	ADW17120	Adw17120	Eucalyptu
932	64	10.5	831	6	ADA55032	Ada55032	Human pro
933	64	10.5	831	7	ABW00424	Abw00424	Human vas
934	64	10.5	831	7	ADJ70697	Adj70697	Human hea
935	64	10.5	831	9	ADV15210	Adv15210	Human vas
936	64	10.5	832	4	ABB62517	Abb62517	Drosophil
937	64	10.5	832	8	ADS96686	Ads96686	Drosophil
938	64	10.5	832	8	ADS96760	Ads96760	Drosophil
939	64	10.5	839	6	ABU11569	Abu11569	Human MDD
940	64	10.5	839	6	ABU11832	Abu11832	Human MDD
941	64	10.5	860	8	ADG22623	Adg22623	Cyanophag
942	64	10.5	884	8	ABM85145	Abm85145	Human dia
943	64	10.5	889	8	ABM85144	Abm85144	Human dia
944	64	10.5	891	8	ABM85143	Abm85143	Human dia
945	64	10.5	917	8	ABM85142	Abm85142	Human dia
946	64	10.5	927	8	ABM85141	Abm85141	Human dia
947	64	10.5	968	3	AAY78946	Aay78946	Polycysti
948	64	10.5	968	4	AAB68450	Aab68450	Amino aci
949	64	10.5	968	8	ADJ75355	Adj75355	Marker ge
950	64	10.5	968	9	ADY15149	Ady15149	PRO polyp
951	64	10.5	968	9	ADY70481	Ady70481	Human bet
952	64	10.5	968	9	AEB51187	Aeb51187	Human PKD
953	64	10.5	1160	6	ABU27908	Abu27908	Protein e
954	64	10.5	5207	8	ADQ91706	Adq91706	Polyketid
955	64	10.5	5207	8	AEB86998	Aeb86998	Streptomy
956	64	10.5	5207	8	AEB86795	Aeb86795	Streptomy
957	63.5	10.4	129	7	ABO67673	Abo67673	Klebsiell
958	63.5	10.4	158	3	AAG22606	Aag22606	Zea mays
959	63.5	10.4	162	8	ADX66948	Adx66948	Plant ful
960	63.5	10.4	168	8	ADX66211	Adx66211	Plant ful
961	63.5	10.4	171	8	ADX93825	Adx93825	Plant ful
962	63.5	10.4	171	8	ADX93811	Adx93811	Plant ful
963	63.5	10.4	176	3	AAG41596	Aag41596	Arabidops
964	63.5	10.4	215	6	ADB12575	Adb12575	Alloiococ
965	63.5	10.4	235	8	ADT58394	Adt58394	Plant pol
966	63.5	10.4	256	8	ADY09613	Ady09613	Plant ful
967	63.5	10.4	277	7	ABO68565	Abo68565	Pseudomon
968	63.5	10.4	329	6	ADB12573	Adb12573	Alloiococ
969	63.5	10.4	332	6	ADB12571	Adb12571	Alloiococ
970	63.5	10.4	336	8	ADX66806	Adx66806	Plant ful
971	63.5	10.4	378	4	ABB69882	Abb69882	Drosophil
972	63.5	10.4	381	7	ADC23955	Adc23955	Protein s
973	63.5	10.4	381	8	ADH36056	Adh36056	Chemical

974	63.5	10.4	381	8	ADG93757	Adg93757 Nitrilase
975	63.5	10.4	381	8	ADI62354	Adi62354 Nitrilase
976	63.5	10.4	381	8	ADI64475	Adi64475 Nitrilase
977	63.5	10.4	429	4	AAU14300	Aau14300 Human nov
978	63.5	10.4	454	7	ABO66401	Abo66401 Klebsiell
979	63.5	10.4	455	8	ADT60865	Adt60865 Plant pol
980	63.5	10.4	476	4	AAM23959	Aam23959 Human EST
981	63.5	10.4	537	9	ABM96369	Abm96369 M. xanthu
982	63.5	10.4	687	6	ABU37808	Abu37808 Protein e
983	63.5	10.4	771	2	AAY34574	Aay34574 Porphorym
984	63.5	10.4	786	2	AAY34431	Aay34431 Porphorym
985	63.5	10.4	792	4	ABG05849	Abg05849 Novel hum
986	63.5	10.4	914	8	ADN46489	Adn46489 Thermococ
987	63.5	10.4	967	4	ABG20905	Abg20905 Novel hum
988	63.5	10.4	969	7	ABO78239	Abo78239 Pseudomon
989	63	10.3	12	5	AAU99715	Aau99715 Human Ghr
990	63	10.3	12	9	ADX83594	Adx83594 Human ghr
991	63	10.3	118	4	AAB46415	Aab46415 H. pylori
992	63	10.3	165	6	ABU35896	Abu35896 Protein e
993	63	10.3	247	2	AAY48472	Aay48472 Human bre
994	63	10.3	247	8	ADO39134	Ado39134 Myelin-ol
995	63	10.3	247	8	ADX76687	Adx76687 Plant ful
996	63	10.3	251	4	AAB70067	Aab70067 Human sec
997	63	10.3	251	5	ABG65506	Abg65506 Human alb
998	63	10.3	251	8	ADL78773	Adl78773 Albumin f
999	63	10.3	273	8	ADY07009	Ady07009 Plant ful
1000	63	10.3	314	4	AAB70085	Aab70085 Human sec

ALIGNMENTS

RESULT 1
AAW87991
ID AAW87991 standard; protein; 117 AA.
XX
AC AAW87991;
XX
DT 07-APR-1999 (first entry)
XX
DE Protein designated zsig33.
XX
KW Zsig33; gastric motility; gastrointestinal inflammation; reflux disease;
KW nutrient absorption regulation; obesity; metabolic disorder.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1. .23
FT /note= "signal peptide"
FT Protein 24. .117
FT /note= "mature protein"
XX
PN WO9842840-A1.
XX
PD 01-OCT-1998.
XX
PF 23-MAR-1998; 98WO-US005620.
XX
PR 24-MAR-1997; 97US-0041102P.
PR 24-MAR-1997; 97US-00822897.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Sheppard PO, Deisher TA;
XX
DR WPI; 1999-070071/06.
DR N-PSDB; AAX04550.
XX
PT Human polypeptide having homology to motilin, zsig33 - useful e.g. to
PT treat gastrointestinal motility disorders, obesity etc. and to identify
PT antagonists to treat gastrointestinal hypermotility.
XX
PS Claim 13; Page 55-56; 69pp; English.
XX
CC The present sequence represents a protein designated Zsig33. The nucleic
CC acids are strongly expressed in stomach tissue. The polypeptide (or
CC allelic variants/orthologs) can be used to stimulate gastric motility,
CC measured as increased transit time or gastric emptying of an ingested
CC substance in mammals. The products are used to treat disorders associated
CC with gastrointestinal cell contractility, secretion of digestive
CC enzymes/acids, gastrointestinal motility, recruitment of digestive
CC enzymes, gastrointestinal inflammation, reflux disease and nutrient
CC absorption regulation. Zsig33 polypeptides may also be important
CC neurologically, since the family of gut-brain peptides to which the
CC homologous protein motilin belongs has been associated with neurological
CC and CNS functions. They may therefore be used e.g. to regulate satiety or
CC treat obesity and other metabolic disorders where neurological feedback
CC modulates nutritional absorption. They are useful to identify zsig33
CC agonists, antagonists and ligands and to produce antibodies
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 2
AAY87236
ID AAY87236 standard; protein; 117 AA.
XX
AC AAY87236;
XX
DT 11-MAY-2000 (first entry)
XX
DE Human signal peptide containing protein HSPP-13 SEQ ID NO:13.
XX
KW Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; nootropic; neuroprotective; cardiovascular; hepatotropic;
KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW Parkinson's disease; Huntington's diseases; ovulatory defect;
KW muscular dystrophy.
XX
OS Homo sapiens.
XX
PN WO200000610-A2.
XX
PD 06-JAN-2000.
XX
PF 25-JUN-1999; 99WO-US014484.
XX
PR 26-JUN-1998; 98US-0090762P.
PR 31-JUL-1998; 98US-0094983P.
PR 01-OCT-1998; 98US-0102686P.
PR 11-DEC-1998; 98US-0112129P.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX
DR WPI; 2000-160673/14.

```
DR   N-PSDB; AAZ98121.
XX
PT   New human signal peptide-containing proteins useful in treatment,
PT   prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
PT   disease.
XX
PS   Claim 1; Page 168-169; 327pp; English.
XX
CC   AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
CC   human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have
CC   anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,
CC   neuroprotective, cardiovascular and antiasthmatic activities, and can be
CC   used in gene therapy. HSPPs can be used to treat or prevent disorders
CC   associated with decreased activity or function of HSPP. Antagonists of
CC   HSPP are used to treat or prevent disorders associated with increased
CC   activity or function of HSPP. Such diseases include cell proliferation
CC   (including cancer), inflammation, cardiovascular, neurological,
CC   reproductive or developmental disorders, (e.g. arteriosclerosis,
CC   cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC   asthma, Crohn's disease, microbial or other infections, congestive or
CC   ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC   diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP
CC   nucleic acids can be used for the recombinant production of HSPP, for
CC   detecting HSPP in standard hybridisation and amplification assays (for
CC   diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
CC   or ribozyme therapeutics, for detecting related sequences or genetic
CC   variations, and for chromosomal mapping. HSPP are also used to raise
CC   specific antibodies (Ab) and to screen for agonists and antagonists
CC   (potential therapeutic agents). Ab are used to diagnose, or monitor, HSPP
CC   -related diseases (in usual immunoassays), as therapeutic antagonists, in
CC   competitive drug screens, and for purification of HSPP from natural
CC   sources
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 3;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 3
AAB20101
ID   AAB20101 standard; protein; 117 AA.
XX
AC   AAB20101;
XX
DT   23-APR-2001  (first entry)
XX
DE   Zsig33 protein.
XX
KW   SGIP; zsig33; anorectic; antidiabetic; somatotropin; somatomedin-C;
KW   nutritional absorption modulator; growth hormone secretagogue; therapy;
KW   human.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1. .23
FT                   /label= Signal_peptide
FT   Protein         24. .117
FT                   /label= Mature_protein
FT   Peptide         24. .34
FT                   /label= SGIP_peptide
FT                   /note= "this peptide is claimed in Claim 1"
XX
PN   WO200100830-A1.
XX
PD   04-JAN-2001.
XX
PF   30-JUN-2000; 2000WO-US018306.
XX
PR   30-JUN-1999;   99US-00345157.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Sheppard PO,  Jaspers SR,  Deisher TA,  Bishop PD;
XX
DR   WPI; 2001-123010/13.
DR   N-PSDB; AAF30033.
XX
PT   Novel variants of SGIP peptides for modulating contractility in duodenum
PT   or jejunum tissue, pancreatic secretion of hormones and digestive
PT   enzymes, inducing growth hormone secretion or modulating gastric
PT   emptying.
XX
PS   Disclosure; 54; 61pp; English.
XX
CC   The present sequence is that of zsig33, a secreted protein with homology
CC   to motilin (see AAB20102). Zsig33 is expressed at high levels in the
CC   stomach, and at lower levels in the small intestine and pancreas. A novel
CC   peptide fragment of zsig33, termed SGIP (see AAB20100), is claimed. SGIP
CC   is a ligand for growth hormone secretagogue receptor, and is therefore
CC   useful for modulating secretion of growth hormone and insulin like growth
CC   factor 1. SGIP, and variant SGIP peptides, are used in claimed methods
CC   for stimulating contractability in duodenum or jejunum tissue, modulating
CC   pancreatic secretion of hormones and digestive enzymes, inducing growth
CC   hormone secretion, and modulating gastric emptying
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 4;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 4
AAB62649
ID   AAB62649 standard; protein; 117 AA.
XX
AC   AAB62649;
XX
DT   23-JUL-2001  (first entry)
XX
DE   Human zsig33 polypeptide.
XX
KW   zsig33; signal transduction; hormone; enzyme; neural development;
KW   gastric contractility; nutrient uptake; digestive; pancreatic; human;
KW   insulin-like growth factor-I; growth hormone; bone; gastrointestinal;
KW   glucose; osteopathic; anorectic; vulnerary; immunomodulator; GHS-R;
KW   G-protein coupled receptor.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         24. .37
FT                   /note= "specifically claimed fragment that binds to the
FT                   GHS-R"
XX
PN   WO200138355-A2.
XX
```

PD 31-MAY-2001.
XX
PF 22-NOV-2000; 2000WO-US032074.
XX
PR 22-NOV-1999; 99US-0166765P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Sheppard PO, Jaspers SR, Deisher TA, Bishop PD;
XX
DR WPI; 2001-355879/37.
DR N-PSDB; AAF83678.
XX
PT Forming reversible peptide receptor complex for purifying cell and
PT peptides, stimulating signal transduction and modulating hormone
PT secretion, involves contacting a receptor with zsig33 polypeptide.
XX
PS Claim 1; Page 93-94; 111pp; English.
XX
CC The invention relates to a method of forming a reversible peptide-
CC receptor complex that involves providing an immobilized receptor, and
CC contacting the receptor with a zsig33 peptide (comprising residues 24-37
CC of AAB62649), where the receptor binds to the zsig33 peptide. The method
CC is useful for purifying cells, purifying a peptide, stimulating signal
CC transduction in a cell expressing a receptor. It is also useful for
CC modulating secretion of hormones, neural development and/or utilization,
CC gastric contractility, nutrient uptake, secretion of digestive and
CC pancreatic enzymes and hormones, secretion of insulin-like growth factor
CC -I, secretion of non-zsig33 proteins. It is useful for modulating growth
CC hormone secretion in a mammal having a disease associated with abnormal
CC levels of growth hormone, such as osteoporosis, bone repair, bone
CC remodeling, low osteoblast levels, cartilage repair and remodeling,
CC skeletal dysplasia, immune suppression, obesity, growth retardation,
CC protein catabolic responses after surgery, cachexia, protein loss,
CC dwarfism, wound healing and ovulation induction, treating a mammal having
CC a metabolic disorder requiring neurological feedback, such as satiety
CC regulation, glucose absorption and metabolism and neuropathy-associated
CC gastrointestinal disorders, and stimulating glucose-induced insulin
CC release in a mammal. The present sequence represents the human zsig33
CC polypeptide, a peptide ligand for the G-protein coupled receptor, GHS-R
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 4; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 5
AAM38890
ID AAM38890 standard; protein; 117 AA.
XX
AC AAM38890;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2035.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US034263.
XX
PR 23-DEC-1999; 99US-00471275.
PR 21-JAN-2000; 2000US-00488725.
PR 25-APR-2000; 2000US-00552317.
PR 20-JUN-2000; 2000US-00598042.
PR 19-JUL-2000; 2000US-00620312.
PR 03-AUG-2000; 2000US-00653450.
PR 14-SEP-2000; 2000US-00662191.
PR 19-OCT-2000; 2000US-00693036.
PR 29-NOV-2000; 2000US-00727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;
PI Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI58046.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders such
PT as central nervous system injuries.
XX
PS Example 3; SEQ ID NO 2035; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and the
CC encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders. Note: The sequence data for this patent did not form
CC part of the printed specification
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 4; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 6
AAB60511
ID AAB60511 standard; protein; 117 AA.
XX
AC AAB60511;
XX
DT 24-APR-2001 (first entry)
XX
DE Human ghrelin preproprotein, SEQ ID NO:5.
XX

```
KW   Growth hormone secretagogue; GHS; ghrelin; precursor; preproprotein;
KW   calcium concentration elevation; infant growth disorder;
KW   growth hormone deficiency.
XX
OS   Homo sapiens.
XX
PN   WO200107475-A1.
XX
PD   01-FEB-2001.
XX
PF   24-JUL-2000; 2000WO-JP004907.
XX
PR   23-JUL-1999;   99JP-00210002.
PR   29-NOV-1999;   99JP-00338841.
PR   26-APR-2000; 2000JP-00126623.
XX
PA   (KANG/) KANGAWA K.
XX
PI   Kangawa K,  Kojima M,  Hosoda H,  Matsuo H,  Minamitake Y;
XX
DR   WPI; 2001-159704/16.
DR   N-PSDB; AAF59645.
XX
PT   New peptide compounds which induce growth hormone secretion and elevate
PT   cell calcium concentrations, useful in treatment and diagnosis of infant
PT   growth disorders.
XX
PS   Claim 3; Page 182; 210pp; Japanese.
XX
CC   The invention relates to a novel peptide compound or its salt which
CC   induces the secretion of growth hormone and/or elevates calcium ion
CC   concentration in cells. The peptides are ghrelin homologues and are
CC   characterised in that at least one amino acid has been substituted by a
CC   modified amino acid and/or a non-amino acid compound. The invention also
CC   encompasses the unmodified peptides; the DNA encoding the peptides;
CC   vectors and host cells comprising such DNA; a method of producing the
CC   peptides comprising recombinant production, optionally followed by
CC   chemical modification; an antibody specific for a peptide of the
CC   invention; and an assay and kit for detecting the peptides. The peptides
CC   of the invention are useful for treating and/or diagnosing diseases
CC   caused by a deficiency in growth hormone expression or activity. In
CC   particular, they are useful for promoting infant growth due to growth
CC   hormone deficiency. The compounds of the invention are safe with no
CC   accompanying side effects. The present sequence represents a ghrelin-type
CC   growth hormone secretagogue (GHS) precursor protein of the invention
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 4;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 7
ABB78319
ID   ABB78319 standard; protein; 117 AA.
XX
AC   ABB78319;
XX
DT   05-DEC-2002  (first entry)
XX
DE   Amino acid sequence of a human zsig33.
XX
KW   Short gastrointestinal peptide; SGIP; zsig33; motilin.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1. .23
FT                   /note= "signal peptide"
FT   Protein         24. .119
FT                   /note= "mature protein"
XX
PN   US6420521-B1.
XX
PD   16-JUL-2002.
XX
PF   30-JUN-2000; 2000US-00608810.
XX
PR   30-JUN-1999;   99US-0141592P.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Sheppard PO,  Jaspers SR,  Deisher TA,  Bishop PD;
XX
DR   WPI; 2002-634794/68.
DR   N-PSDB; ABV72214.
XX
PT   New Short Gastrointestinal Peptide, which has homology to motilin, useful
PT   for preventing, diagnosing and treating gastrointestinal disorders.
XX
PS   Disclosure; Col 39-40; 23pp; English.
XX
CC   The present sequence represents human zsig33. The specification describes
CC   a short gastrointestinal peptide (SGIP), which is derived from zsig33.
CC   SGIP has homology to motilin. The SGIP peptide may be used in the
CC   prevention, diagnosis and treatment of diseases associated with
CC   inappropriate SGIP expression. For example, SGIP may be used to treat
CC   disorders associated with decreased expression by rectifying mutations or
CC   deletions in a patient's genome that affect the activity of SGIP by
CC   expressing inactive proteins or to supplement the patients own production
CC   of SGIP. SGIP may also be used as an antigen in the production of
CC   antibodies against SGIP and in assays to identify modulators of SGIP
CC   expression and activity. The anti-SGIP antibodies, agonists and
CC   antagonists may also be used to regulate expression and activity. The
CC   anti-SGIP antibodies may also be used as diagnostic agents for detecting
CC   the presence of SGIP in samples
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 5;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 8
AAE23838
ID   AAE23838 standard; protein; 117 AA.
XX
AC   AAE23838;
XX
DT   10-SEP-2002  (first entry)
XX
DE   Human zsig33 protein.
XX
KW   Human; zsig33-like peptide; gastric contractility; nutrient uptake;
KW   growth hormone; digestive enzyme; restorative therapy; gene therapy;
KW   protein therapy; gastrointestinal; endocrine; anabolic.
XX
OS   Homo sapiens.
```

```
XX
PN   US2002055156-A1.
XX
PD   09-MAY-2002.
XX
PF   10-MAY-2001; 2001US-00853253.
XX
PR   11-MAY-2000; 2000US-0203300P.
XX
PA   (JASP/) JASPERS S R.
PA   (SHEP/) SHEPPARD P O.
PA   (DEIS/) DEISHER T A.
PA   (BISH/) BISHOP P D.
XX
PI   Jaspers SR,  Sheppard PO,  Deisher TA,  Bishop PD;
XX
DR   WPI; 2002-443750/47.
DR   N-PSDB; AAD38238.
XX
PT   ZSIG33-Like peptides and polynucleotides, useful for modulating gastric
PT   contractility, nutrient uptake, growth hormones and/or secretion of
PT   digestive/pancreatic enzymes and hormones.
XX
PS   Disclosure; Page 27; 34pp; English.
XX
CC   The invention relates to zsig33-like peptides and their corresponding
CC   nucleic acids and methods for modulating gastric contractility, nutrient
CC   uptake, growth hormones, secretion of digestive enzymes and hormones. The
CC   sequences of the invention are used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate ZSIG33 expression.
CC   The nucleic acids of the invention and their complements are used as DNA
CC   probes in diagnostic assays to detect and quantitate the presence of
CC   similar nucleic acids in samples, and therefore which patients may be in
CC   need of restorative therapy. The ZSIG33 peptides are used as antigens in
CC   the production of antibodies against ZSIG33 and in assays to identify
CC   modulators of ZSIG33 expression and activity. The anti-ZSIG33 antibodies
CC   and antagonists are used to down regulate expression and activity. The
CC   anti-ZSIG33 antibodies are also used as diagnostic agents for detecting
CC   the presence of ZSIG33 in samples (e.g. by enzyme linked immunosorbent
CC   assay (ELISA)). The peptides and nucleic acids of the invention are used
CC   to modulate gastric contractility, nutrient uptake, growth hormones, the
CC   secretion of digestive enzymes and hormones, and/or secretion of enzymes
CC   and/or hormones in the pancreas. zsig33-like DNA is used in gene therapy
CC   and zsig33-like peptide is used in protein therapy. The present sequence
CC   is human zsig33 protein
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 5;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 9
AAE15883
ID   AAE15883 standard; protein; 117 AA.
XX
AC   AAE15883;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Human zsig33 protein.
XX
KW   Human; zsig33-like peptide; ZS33LP; immunity; developmental process;
KW   infection; human immunodeficiency virus; vaccine; antihypoglycaemic;
KW   adsorption enhancer; gastrointestinal disease; growth related disease;
KW   inflammation; gene therapy; growth regulation; blood vessel formation;
KW   HIV; zsig33 protein.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..23
FT                   /label= Signal_peptide
FT   Protein         24..117
FT                   /note= "Human mature zsig33 protein"
XX
PN   WO200187933-A2.
XX
PD   22-NOV-2001.
XX
PF   10-MAY-2001; 2001WO-US015091.
XX
PR   11-MAY-2000; 2000US-00569271.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Jaspers SR,  Sheppard PO,  Deisher TA,  Bishop PD;
XX
DR   WPI; 2002-082982/11.
DR   N-PSDB; AAD25759.
XX
PT   New polypeptides, useful for modulating gastric contractility, nutrient
PT   uptake, pancreatic secretion of hormones, digestive enzymes and treating
PT   gastrointestinal and growth related diseases, comprises zsig33-like
PT   peptides.
XX
PS   Disclosure; Page 80-81; 89pp; English.
XX
CC   The invention relates to zsig33-like peptides (ZS33LP) including zsig33-
CC   linker, zsig33-beta, zsig33-gamma, zsig33-delta and zsig33-epsilon
CC   peptides and nucleic acid molecules encoding such zsig33-like peptides.
CC   ZS33LP peptides activate the immune system in boosting immunity to
CC   infectious diseases, treating immunocompromised patients such as human
CC   immunodeficiency virus (HIV) patients, in improving vaccines and in
CC   treatment of bacterial, viral, protozoal and fungal infections. Peptides
CC   of the invention are used to identify and isolate receptors involved in
CC   growth regulation in the liver, blood vessel formation and other
CC   developmental processes. They are useful for evaluating functions of
CC   hypothalamus-pituitary-adrenal axis, to modulate growth and/or
CC   differentiation of tumour cells, as additives to anti- hypoglycaemic
CC   preparations containing glucose and as adsorption enhancers for oral
CC   drugs which require fast nutrient action and to stimulate glucose-induced
CC   insulin release. They are also useful as research reagents for the
CC   expansion, differentiation, growth factor and hormone secretion and/or
CC   cell-cell interactions of tissues associated with gastrointestinal
CC   system, brain and central nervous system. These molecules are useful for
CC   treating dysfunction associated with contractile tissues or to suppress
CC   or enhance contractility in vivo and to treat gastrointestinal and growth
CC   related diseases. ZS33LP peptides, nucleic acids and/or antibodies are
CC   useful for treating disorders associated with gastrointestinal
CC   contractility, secretion of digestive enzymes, hormone and acids,
CC   secretion of hormones in the pancreas and/or brain, gastrointestinal
CC   motility, recruitment of digestive enzymes, inflammation and regulation
CC   of nutrient absorption. Sequences of the invention are useful in gene
CC   therapy. The present sequence is human zsig33 protein
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 5;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

```
                     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 10
ABU58046
ID   ABU58046 standard; protein; 117 AA.
XX
AC   ABU58046;
XX
DT   14-APR-2003  (first entry)
XX
DE   Human PRO polypeptide #78.
XX
KW   Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;
KW   horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;
KW   antibody-dependent enzyme mediated prodrug therapy.
XX
OS   Homo sapiens.
XX
PN   US2003027163-A1.
XX
PD   06-FEB-2003.
XX
PF   15-NOV-2001; 2001US-00997666.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
```

PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 11
ABU59124
ID ABU59124 standard; protein; 117 AA.
XX
AC ABU59124;
XX
DT 28-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO1066.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2002132252-A1.
XX
PD 19-SEP-2002.
XX
PF 14-NOV-2001; 2001US-00990442.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-247083/24.
DR N-PSDB; ABX80294.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT are therapeutically useful for enhancing immune response and in cancer
PT treatments.
XX
PS Claim 12; Fig 186; 648pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are
CC thus useful for treating sports injuries, and arthritis. This is the
CC amino acid sequence of a novel human PRO protein
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 12
ABU82636
ID ABU82636 standard; protein; 117 AA.
XX
AC ABU82636;
XX
DT 26-JUN-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1066.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW cardiac insufficiency disorders; angiogenesis; wound healing;
KW cancerous tumour; immune response; retinal disorder; sight loss;
KW retinitis pigmentosum; age-related macular degeneration; AMD;
KW kidney disorder; Berger disease; nephropathy; dermatitis; herpetiformis;
KW Crohn's disease; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003032023-A1.
XX
PD 13-FEB-2003.
XX
PF 14-NOV-2001; 2001US-00990711.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 13
ABO17836
ID ABO17836 standard; protein; 117 AA.
XX
AC ABO17836;
XX
DT 26-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing.
XX
OS Homo sapiens.
XX
PN US2003032156-A1.
XX
PD 13-FEB-2003.
XX
PF 06-MAY-2002; 2002US-00140474.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.

```
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-341980/32.
DR   N-PSDB; ACD24073.
XX
PT   New secreted and transmembrane PRO nucleic acids, for treating
PT   inflammation, organ failure, atherosclerosis, cardiac injury,
PT   infertility, birth defects, premature aging, axquired immunodeficiency
PT   syndrome (AIDS), or cancer.
XX
PS   Claim 12; Fig 442; 660pp; English.
XX
CC   The invention describes an isolated nucleic acid (I) comprising, or which
CC   has 80 % sequence identity to, or the full-length coding sequence of, one
CC   of 275 nucleotide sequences, and which encodes a corresponding
CC   polypeptide selected from 275 amino acid sequences, where all sequences
CC   are given in the specification. The polypeptide encoded by (I) is used to
CC   detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC   PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC   release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC   the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC   the proliferation or differentiation of cells or gene expression,
CC   stimulate the release of proteoglycans, stimulate the release of cytokine
CC   from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC   to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
CC   acid and polypeptide encoded by it, are useful for treating inflammatory
CC   diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC   birth defects, premature aging, acquired immunodeficiency syndrome
CC   (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC   hybridisation probes, in chromosome and gene mapping, and in generating
CC   antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC   diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC   This is the amino acid sequence of a novel human secreted and
CC   transmembrane PRO polypeptide
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 14
ABU60555
ID   ABU60555 standard; protein; 117 AA.
XX
AC   ABU60555;
XX
DT   01-MAY-2003  (first entry)
XX
DE   Human secreted/transmembrane protein, #108.
XX
KW   Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;
KW   diagnostic; therapeutic; gene therapy.
XX
OS   Homo sapiens.
XX
PN   US2002160384-A1.
XX
PD   31-OCT-2002.
XX
PF   14-NOV-2001; 2001US-00992598.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
```

PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-288106/28.
DR N-PSDB; ABX90272.
XX
PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
PS Claim 12; Fig 186; 650pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful in gene therapy, in chromosome
CC identification, as chromosome markers, or in generating probes. The PRO
CC polypeptides are useful as molecular markers for protein electrophoresis,
CC and the isolated nucleic acids may be used for recombinantly expressing
CC those markers. The PRO polypeptides and nucleic acids may also be used in
CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
CC PRO, and in affinity purification of PRO from recombinant cell culture or
CC natural sources. The sequences presented in ABU60478-ABU60624 are the PRO
CC polynucleotides of the invention. Note: The sequence data for this patent
CC is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 15
ABU13937
ID ABU13937 standard; protein; 117 AA.
XX
AC ABU13937;
XX
DT 26-FEB-2003 (first entry)
XX
DE Human PRO1066 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive.
XX
OS Homo sapiens.
XX
PN US2002103125-A1.
XX
PD 01-AUG-2002.
XX
PF 20-NOV-2001; 2001US-00989731.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.

```
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   06-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
XX
PA   (GETH ) GENENTECH LTD.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2003-102117/09.
DR   N-PSDB; ABX64118.
XX
PT   Novel secreted and transmembrane polypeptide for modulating biological
PT   activity of cell expressing the polypeptide, identifying agonists or
PT   antagonists of polypeptide, and as molecular weight markers.
XX
PS   Claim 12; Fig 186; 649pp; English.
XX
CC   The present invention relates to the isolation of novel human PRO
CC   polypeptides, and the polynucleotide sequences encoding them. The PRO
CC   polypeptides are secreted and transmembrane proteins. The PRO
CC   polypeptides are useful for detecting other PRO polypeptides, for linking
CC   bioactive molecules to cells expressing PRO polypeptides, for modulating
CC   biological activities of cells expressing PRO polypeptides, and for for
CC   identifying agonists or antagonists. The polynucleotide sequences
CC   encoding PRO polypeptides are useful as hybridisation probes, in
CC   chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC   in the preparation of PRO polypeptides, for generating transgenic animals
CC   or knockout animals, to construct hybridisation probes for mapping the
CC   gene which encodes the PRO polypeptide, and for the genetic analysis of
CC   individuals with genetic disorders, in gene therapy, for chromosome
CC   identification, as chromosome markers, and for generating probes for PCR,
CC   Northern analysis, Southern analysis and Western analysis. ABU13860-
CC   ABU14006 represent the human PRO polypeptides of the invention. Note: The
CC   sequence data for this patent was obtained in electronic format directly
CC   from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 16
ABU81090
ID   ABU81090 standard; protein; 117 AA.
XX
AC   ABU81090;
XX
DT   23-JUN-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO polypeptide; secreted and transmembrane protein;
KW   anti-PRO antibody; diagnostic assay; gene expression; diabetes;
KW   bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KW   sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
KW   hearing loss; coagulation disorder; stroke; heart attack; cardiant;
KW   antidiabetic; anorectic; vulnerary; antiarthritic; osteopathic;
KW   antirheumatic; auditory; cerebroprotective; angiogenic.
XX
OS   Homo sapiens.
XX
PN   US2003004311-A1.
XX
PD   02-JAN-2003.
XX
PF   19-DEC-2001; 2001US-00028072.
XX
PR   18-JUN-1997;   97US-0049911P.
PR   26-AUG-1997;   97US-0056974P.
PR   17-SEP-1997;   97US-0059113P.
PR   17-SEP-1997;   97US-0059115P.
PR   17-SEP-1997;   97US-0059117P.
PR   17-SEP-1997;   97US-0059122P.
```

```
PR   17-SEP-1997;   97US-0059184P.
PR   18-SEP-1997;   97US-0059263P.
PR   19-SEP-1997;   97US-0059352P.
PR   19-SEP-1997;   97US-0059588P.
PR   24-SEP-1997;   97US-0059836P.
PR   17-OCT-1997;   97US-0062250P.
PR   17-OCT-1997;   97US-0062285P.
PR   17-OCT-1997;   97US-0062287P.
PR   17-OCT-1997;   97US-0063755P.
PR   24-OCT-1997;   97US-0062814P.
PR   24-OCT-1997;   97US-0062816P.
PR   24-OCT-1997;   97US-0063045P.
PR   24-OCT-1997;   97US-0063082P.
PR   24-OCT-1997;   97US-0063127P.
PR   27-OCT-1997;   97US-0063327P.
PR   27-OCT-1997;   97US-0063329P.
PR   28-OCT-1997;   97US-0063550P.
PR   28-OCT-1997;   97US-0063561P.
PR   29-OCT-1997;   97US-0063704P.
PR   29-OCT-1997;   97US-0063733P.
PR   29-OCT-1997;   97US-0063735P.
PR   29-OCT-1997;   97US-0063738P.
PR   03-NOV-1997;   97US-0064248P.
PR   07-NOV-1997;   97US-0064809P.
PR   12-NOV-1997;   97US-0065186P.
PR   17-NOV-1997;   97US-0065846P.
PR   21-NOV-1997;   97US-0066364P.
PR   24-NOV-1997;   97US-0066453P.
PR   24-NOV-1997;   97US-0066511P.
PR   24-NOV-1997;   97US-0066770P.
PR   11-DEC-1997;   97US-0069212P.
PR   11-DEC-1997;   97US-0069278P.
PR   11-DEC-1997;   97US-0069334P.
PR   16-DEC-1997;   97US-0069694P.
PR   23-JAN-1998;   98US-0072320P.
PR   04-FEB-1998;   98US-0073612P.
PR   09-FEB-1998;   98US-0074086P.
PR   09-FEB-1998;   98US-0074092P.
PR   12-MAR-1998;   98US-0077791P.
PR   20-MAR-1998;   98US-0078910P.
PR   25-MAR-1998;   98US-0079294P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079728P.
PR   31-MAR-1998;   98US-0080165P.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-352836/33.
DR   N-PSDB; ACA67214.
XX
PT   New isolated PRO polypeptide useful for treating diabetes, rheumatoid
PT   arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
PT   heart attack.
XX
PS   Claim 12; Fig 442; 643pp; English.
XX
CC   The present invention relates to the isolation of novel human PRO
CC   polypeptides, and the polynucleotide sequences encoding them. The PRO
CC   polypeptides are secreted and transmembrane proteins. The PRO
CC   polypeptides and polynucleotides are useful for preparing a medicament
CC   useful in the treatment of diabetes, bone and/or cartilage disorders
CC   (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
CC   hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
CC   (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
CC   assays for PRO, by detecting its expression in specific cells, tissues or
CC   serum, and for affinity purification of PRO from recombinant cell culture
CC   or natural sources. ABU80870-ABU81144 represent the human PRO
CC   polypeptides of the invention. Note: The sequence data for this patent
CC   was obtained in electronic format directly from the USPTO web site at
CC   seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 17
ABU72522
ID   ABU72522 standard; protein; 117 AA.
XX
AC   ABU72522;
XX
```

DT 17-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; cytostatic; anti-HIV;
KW virucide; hepatotropic; antiinflammatory; neuroprotective; gene therapy;
KW PRO; pharmaceutical; diagnostic; biosensor; bioreactor; malignancy;
KW cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;
KW lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;
KW drug screening.
XX
OS Homo sapiens.
XX
PN US2003003531-A1.
XX
PD 02-JAN-2003.
XX
PF 19-NOV-2001; 2001US-00989734.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-352829/33.
DR N-PSDB; ACA64340.
XX
PT New genes and secreted and transmembrane polypeptides (e.g. PRO183 or
PT PRO184), useful for treating or diagnosing e.g. ovarian cancer, Kaposi's
PT sarcoma, leukemia, lymphoma, hepatitis B, multiple sclerosis or Crohn's
PT disease.
XX
PS Claim 12; Fig 186; 663pp; English.
XX
CC The invention describes a new isolated nucleic acid molecule comprising
CC the full length coding sequence of the DNA deposited with the American
CC Type Culture Collection (e.g. ATCC Deposit No. 209621, 552-PTA, 819-PTA,
CC 209439, 203135, etc); or a sequence with at least 80% identity to a DNA
CC encoding a PRO polypeptide. The PRO polypeptides or polynucleotides are
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These
CC are particularly useful for detecting or treating e.g. malignancies or
CC cancers (e.g. ovarian cancer, colorectal cancer, Kaposi's sarcoma,
CC leukaemia or lymphoma), hepatitis B, multiple sclerosis, or Crohn's
CC disease in mammals. The PRO polypeptides are useful in drug screening,
CC particularly as targets for therapeutic intervention in these diseases,
CC and in the diagnostic determination of the presence of these diseases.
CC The PRO polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.

```
CC   The PRO genes may also be used in gene therapy, particularly for
CC   replacing a defective gene. This is the amino acid sequence of a novel
CC   human secreted and transmembrane PRO polypeptide
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 18
ABU66790
ID   ABU66790 standard; protein; 117 AA.
XX
AC   ABU66790;
XX
DT   23-MAY-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO polypeptide; secreted and transmembrane protein;
KW   tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW   differentiation; chondrocyte; tumour; genetic disorder; cytostatic.
XX
OS   Homo sapiens.
XX
PN   US2003036180-A1.
XX
PD   20-FEB-2003.
XX
PF   09-MAY-2002; 2002US-00143114.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
```

```
XX
DR   WPI; 2003-332040/31.
DR   N-PSDB; ACA03823.
XX
PT   New secreted and transmembrane PRO nucleic acids, useful for gene
PT   therapy, in chromosome and gene mapping, as chromosome markers, in tissue
PT   typing, and in chromosome identification.
XX
PS   Claim 12; Fig 442; 660pp; English.
XX
CC   The present invention relates to the isolation of novel human PRO
CC   polypeptides, and the polynucleotide sequences encoding them. The PRO
CC   polypeptides are secreted and transmembrane proteins. The PRO
CC   polypeptides are useful for detecting other PRO polypeptides, for linking
CC   bioactive molecules to cells expressing PRO polypeptides, for modulating
CC   biological activities of cells expressing PRO polypeptides, and for for
CC   identifying agonists or antagonists. The PRO polypeptides are useful for
CC   for stimulating the release of tumour necrosis factor (TNF)-alpha from
CC   human blood, for stimulating the proliferation or differentiation of
CC   chondrocytes, and detecting the presence of tumours. The polynucleotide
CC   sequences encoding PRO polypeptides are useful as hybridisation probes,
CC   in chromosome and gene mapping, in the generation of antisense RNA and
CC   DNA, in the preparation of PRO polypeptides, for generating transgenic
CC   animals or knockout animals, for the genetic analysis of individuals with
CC   genetic disorders, and in gene therapy. ABU66570-ABU66844 represent the
CC   human PRO polypeptides of the invention. Note: The sequence data for this
CC   patent was obtained in electronic format directly from the USPTO web site
CC   at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 19
ABU59871
ID   ABU59871 standard; protein; 117 AA.
XX
AC   ABU59871;
XX
DT   13-MAY-2003  (first entry)
XX
DE   Novel secreted and transmembrane protein PRO1066.
XX
KW   Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW   cardiac insufficiency disorder; cancer; tumour; immune response;
KW   adrenal cortical capillary endothelial growth; c-fos induction;
KW   vascular endothelial growth factor inhibition; VEGF inhibition;
KW   endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW   retinal neurons cell survival; rod photoreceptor cell survival;
KW   retinal disorder; retinitis pigmentosum; kidney disorder;
KW   mammalian kidney mesangial cell proliferation; Berger disease;
KW   dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW   chondrocyte redifferentiation; sports injury; arthritis.
XX
OS   Homo sapiens.
XX
PN   US2003017563-A1.
XX
PD   23-JAN-2003.
XX
PF   07-MAY-2002; 2002US-00140808.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
```

PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-148238/14.
DR N-PSDB; ABX89361.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 442; 659pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are
CC thus useful for treating sports injuries, and arthritis. This is the
CC amino acid sequence of a novel human PRO protein
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 20
ABU59271
ID ABU59271 standard; protein; 117 AA.
XX
AC ABU59271;
XX
DT 22-APR-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #108.
XX
KW Human; PRO; secreted; transmembrane; pharmaceutical; diagnostic;
KW biosensor; bioreactor; tumour; therapeutic; gene therapy;
KW tumour-associated antigenic target; TAT; ADEPT;
KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003027162-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-00997428.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;

```
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 21
ABO25968
ID   ABO25968 standard; protein; 117 AA.
XX
AC   ABO25968;
XX
DT   10-SEP-2003  (first entry)
XX
DE   Human PRO1066 polypeptide.
XX
KW   Human; PRO polypeptide; secreted protein; transmembrane protein;
KW   genetic disorder; antibacterial; immunosuppressive.
XX
OS   Homo sapiens.
XX
PN   US2002127576-A1.
XX
PD   12-SEP-2002.
XX
PF   14-NOV-2001; 2001US-00991073.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   06-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2003-340824/32.
DR   N-PSDB; ACD44308.
XX
PT   Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT   and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT   and are therapeutically useful for enhancing immune responses.
XX
PS   Claim 12; Fig 186; 661pp; English.
XX
CC   The present invention relates to the isolation of novel human PRO
CC   polypeptides, and the polynucleotide sequences encoding them. The PRO
CC   polypeptides are secreted and transmembrane proteins. The PRO
```

```
CC   polypeptides are useful for detecting other PRO polypeptides, for linking
CC   bioactive molecules to cells expressing PRO polypeptides, for modulating
CC   biological activities of cells expressing PRO polypeptides, and for for
CC   identifying agonists or antagonists. The polynucleotide sequences
CC   encoding PRO polypeptides are useful as hybridisation probes, in
CC   chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC   in the preparation of PRO polypeptides, for generating transgenic animals
CC   or knockout animals, to construct hybridisation probes for mapping the
CC   gene which encodes the PRO polypeptide, and for the genetic analysis of
CC   individuals with genetic disorders, in gene therapy, for chromosome
CC   identification, as chromosome markers, and for generating probes for PCR,
CC   Northern analysis, Southern analysis and Western analysis. ABO25891-
CC   ABO26037 represent the human PRO polypeptides of the invention. Note: The
CC   sequence data for this patent was obtained in electronic format directly
CC   from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 22
ABO25061
ID   ABO25061 standard; protein; 117 AA.
XX
AC   ABO25061;
XX
DT   05-SEP-2003  (first entry)
XX
DE   Human secreted/transmembrane protein (PRO) #221.
XX
KW   Human; PRO; secreted protein; transmembrane protein; tumour; cytostatic;
KW   gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;
KW   proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;
KW   PBMC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;
KW   chondrocyte cell proliferation; chondrocyte cell differentiation;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell; A-peptide; factor VIIA.
XX
OS   Homo sapiens.
XX
PN   US2003036179-A1.
XX
PD   20-FEB-2003.
XX
PF   10-MAY-2002; 2002US-00142431.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
```

```
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-466355/44.
DR   N-PSDB; ACD42015.
XX
PT   New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT   PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy.
XX
PS   Claim 12; Fig 442; 659pp; English.
XX
CC   The invention relates to an isolated nucleic acid comprising at least 80%
CC   sequence identity to a PRO (secreted and transmembrane protein) cDNA
CC   comprising a nucleic acid (a) encoding a PRO polypeptide, or its
CC   extracellular domain (with or without its associated signal peptide),
CC   which comprises any of the 275 120-850 residue amino acid sequences,
CC   given in the specification; (b) comprising any of the 275 300-3500
CC   nucleotide sequences, given in the specification; or (c) comprising the
CC   full-length coding sequence of the nucleotide sequences given in the
CC   specification, or of the DNA deposited under any of the American Type
CC   Culture Collection (ATCC) Accession Numbers listed in the specification.
CC   Also included are a vector comprising the novel nucleic acid, a host cell
CC   comprising the vector, producing a PRO polypeptide, the isolated PRO
CC   polypeptides detailed above, a chimaeric molecule comprising the PRO
CC   polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC   antibody, detecting a PRO polypeptide in a sample suspected of containing
CC   the PRO polypeptide, linking a bioactive molecule to a cell expressing a
CC   PRO polypeptide, modulating at least one biological activity of a cell
CC   expressing a PRO polypeptide, stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
CC   cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
CC   modulating the uptake of glucose or FFA by skeletal muscle cells or
CC   adipocyte cells, stimulating the proliferation or differentiation of
CC   chondrocyte cells (or proliferation of or gene expression in pericyte
CC   cells), stimulating the proliferation of inner ear utricular supporting
CC   cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
CC   binding of A-peptide to factor VIIA, or differentiation of adipocyte
CC   cells, detecting the presence of a tumour in a mammal and an
CC   oligonucleotide probe derived from any of the nucleotide sequences given
CC   in the specification. The polynucleotide is useful in molecular biology,
CC   including uses as hybridisation probes, in chromosome and gene mapping,
CC   in generating antisense RNA and DNA, and in gene therapy. The
CC   polynucleotide may also be used in preparing PRO polypeptides by
CC   recombinant techniques, and in generating either transgenic animals or
CC   knock-out animals which, in turn, are useful in the development and
CC   screening of therapeutically useful reagents. The PRO polypeptide or the
CC   antibody is used in preparing a medicament for treating a condition
CC   responsive to the polypeptide or antibody, such as tumours, and in
CC   various diagnostic assays. The present sequence rpereeents a PRO
CC   polypeptide
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 23
ABU58977
ID   ABU58977 standard; protein; 117 AA.
XX
AC   ABU58977;
XX
DT   16-APR-2003  (first entry)
XX
DE   Human secreted/transmembrane protein, #108.
XX
KW   Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;
KW   diagnostic; biosensor; bioreactor; tumour; therapeutic; colon cancer;
KW   lung cancer; breast cancer; cancer; gene therapy.
XX
OS   Homo sapiens.
XX
PN   US2002142961-A1.
XX
PD   03-OCT-2002.
XX
PF   19-NOV-2001; 2001US-00989721.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
```

PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-155950/15.
XX
PT New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
PT PRO361 or PRO846) useful as targets for therapeutic intervention in
PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers.
XX
PS Claim 12; Fig 186; 647pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful as pharmaceuticals, diagnostics,
CC biosensors or bioreactors, for detecting or treating e.g. tumours in
CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
CC colon, lung or breast cancers) and diagnostic determination of the
CC presence of these cancers. The PRO polypeptides are also useful as
CC molecular weight markers or for chromosome identification. The PRO genes
CC are useful as hybridisation probes or for screening libraries of human
CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
CC therapy, particularly for replacing a defective gene. The sequences
CC presented in ABU58900-ABU59046 are the PRO polypeptides of the invention
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 24
ABU92355
ID ABU92355 standard; protein; 117 AA.
XX
AC ABU92355;
XX
DT 16-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO; PRO183; PRO184; PRO185;
KW PRO943; PRO1133; PRO331; PRO1387; PRO363; PRO5723; PRO1114; PRO3301;
KW PRO9940; PRO1181; PRO7170; PRO361; PRO846; bioactive molecule; toxin;
KW radiolabel; antibody; cell death; tissue typing; gene therapy;
KW cytostatic; chromosome mapping; gene mapping; transgenic animal;
KW knockout animal; immunohistochemical staining.
XX
OS Homo sapiens.
XX
PN US2003022187-A1.
XX
PD 30-JAN-2003.
XX
PF 14-NOV-2001; 2001US-00993667.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 22-JUN-1998; 98US-0090282P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 20-FEB-1999; 99WO-US030911.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.

```
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 25
AAE33409
ID   AAE33409 standard; protein; 117 AA.
XX
AC   AAE33409;
XX
DT   02-APR-2003  (first entry)
XX
DE   Human preproghrelin protein.
XX
KW   Ghrelin; preproghrelin; GHS-R 1b; benign prostatic hyperplasia; therapy;
KW   breast; cervical; uterine; choriocarcinoma; prostate; ovary; cytostatic;
KW   cancer; human.
XX
OS   Homo sapiens.
XX
PN   WO200290387-A1.
XX
PD   14-NOV-2002.
XX
PF   10-MAY-2002; 2002WO-AU000582.
XX
PR   10-MAY-2001; 2001AU-00004919.
PR   17-DEC-2001; 2001AU-00009567.
XX
PA   (UYQU-) UNIV QUEENSLAND TECHNOLOGY.
XX
PI   Chopin LK,  Jeffery PL,  Herington AC;
XX
DR   WPI; 2003-111957/10.
DR   N-PSDB; AAD50725.
XX
PT   Identifying a cancer cell or tissue for treating prostate, ovarian,
PT   breast cancer, or benign prostatic hyperplasia, by detecting the
PT   expression of a ghrelin, an exon-3 deleted preproghrelin and/or a GHS-R
PT   1b proteins or nucleic acids.
XX
PS   Example 1; Fig 1; 50pp; English.
XX
CC   The invention relates to a method for identifying a cancer cell or tissue
CC   of the reproductive system by detecting expression of a ghrelin, an exon-
CC   3 deleted preproghrelin and/or a GHS-R 1b proteins or nucleic acids. The
CC   antibodies, exon 3-deleted form of preproghrelin and antagonists are
CC   useful for treating cancer of the reproductive system such as prostate,
CC   ovarian, breast, cervical or uterine cancer, choriocarcinoma or benign
CC   prostatic hyperplasia. The present sequence is human preproghrelin
CC   protein
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 26
ABU59420
ID   ABU59420 standard; protein; 117 AA.
XX
AC   ABU59420;
XX
DT   22-APR-2003  (first entry)
XX
DE   Novel human secreted or transmembrane protein PRO1184.
XX
KW   Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW   cardiac insufficiency disorder; cancer; tumour; immune response;
KW   adrenal cortical capillary endothelial growth; c-fos induction;
KW   vascular endothelial growth factor inhibition; VEGF inhibition;
KW   endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW   retinal neurons cell survival; rod photoreceptor cell survival;
KW   retinal disorder; retinitis pigmentosum; kidney disorder;
KW   mammalian kidney mesangial cell proliferation; Berger disease;
KW   dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW   chondrocyte redifferentiation; sports injury; arthritis.
XX
OS   Homo sapiens.
XX
PN   US2003027985-A1.
XX
PD   06-FEB-2003.
XX
PF   14-NOV-2001; 2001US-00990562.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
```

PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;

```
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 27
ABU67066
ID   ABU67066 standard; protein; 117 AA.
XX
AC   ABU67066;
XX
DT   27-MAY-2003  (first entry)
XX
DE   Human secreted/transmembrane, PRO, protein SEQ ID 442.
XX
KW   Human; secreted protein; transmembrane protein; PRO;
KW   inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW   infertility; birth defects; premature aging; AIDS; biosensor;
KW   acquired immunodeficiency syndrome; cancer; diabetic complication;
KW   bioreactor; tumour.
XX
OS   Homo sapiens.
XX
PN   US20030032155-A1.
XX
PD   13-FEB-2003.
XX
PF   03-MAY-2002; 2002US-00137865.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-331925/31.
DR   N-PSDB; ACA04244.
XX
PT   New secreted and transmembrane nucleic acids and polypeptides, designated
PT   as PRO, useful for treating inflammation, organ failure, atherosclerosis,
```

PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 442; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising, or which is
CC at least 80% identical to, or the full-length coding sequence of, any of
CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
CC (one of 275 secreted or transmembrane proteins). The nucleic acid further
CC comprises the full-length coding sequence of the DNA deposited under
CC American Type Culture Collection (ATCC) accession number in a list given
CC in the specification. Also included are vectors and host cells for
CC producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO
CC extracellular domains and mature sequences, methods of detecting PRO
CC proteins, methods for stimulating the release of TNF-alpha (tumour
CC necrosis factor alpha) from human blood, (and the proliferation of
CC differentiation of chondrocyte cells, the proliferation of, or gene
CC expression in pericyte cells, the release or proteoglycans from
CC cartilage, proliferation of inner ear urticular supporting cells, the
CC proliferation of T-lymphocyte cells, the release of a cytokine from
CC peripheral blood mononuclear cells (PBMC), or the proliferation of
CC endothelial cells), a method for modulating the uptake of glucose or free
CC fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the
CC binding of A-peptide to factor VIIA, or the differentiation of adipocyte
CC cells, a method for detecting the presence of a tumour in a mammal and an
CC oligonucleotide probe derived from any of the nucleotide sequences cited
CC above. The nucleic acids and polypeptides are useful for treating
CC inflammatory diseases, organ failure, atherosclerosis, cardiac injury,
CC infertility, birth defects, premature aging, AIDS (acquired
CC immunodeficiency syndrome), cancer, or diabetic complications. The
CC nucleic acids are useful as hybridisation probes, in chromosome and gene
CC mapping, and in generating antisense RNA or DNA. The polypeptides are
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both
CC are useful in tissue typing. The present sequence represents a PRO
CC protein of the invention
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 28
ABU92186
ID ABU92186 standard; protein; 117 AA.
XX
AC ABU92186;
XX
DT 16-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO; nootropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN US2003017476-A1.
XX
PD 23-JAN-2003.
XX
PF 20-NOV-2001; 2001US-00989724.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.

PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 29
ABU10892
ID ABU10892 standard; protein; 117 AA.
XX
AC ABU10892;
XX
DT 04-FEB-2003 (first entry)
XX
DE Human PRO polypeptide #78.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide; toxin;
KW radiolabel; cell death; gene mapping; chromosome mapping;
KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
KW antibacterial.
XX
OS Homo sapiens.
XX
PN US2002123463-A1.
XX
PD 05-SEP-2002.
XX
PF 19-NOV-2001; 2001US-00989732.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-066810/06.
DR N-PSDB; ABX17082.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 12; Fig 186; 655pp; English.
XX
CC The invention relates to a secreted and transmembrane polypeptide, termed
CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
CC useful for detecting PRO polypeptides and for linking a bioactive
CC molecule to a cell expressing the above polypeptides, where the bioactive
CC molecule is a toxin, radiolabel or an antibody. The bioactive material
CC causes the death of the cell. The polypeptide is useful for identifying
CC agonists or antagonists of the PRO polypeptide, for preparing variants of
CC PRO, as a molecular weight marker for protein electrophoresis purposes
CC and the PRO polynucleotide is useful for recombinantly expressing those
CC markers. The polynucleotide is also useful as a hybridisation probe, in
CC chromosome and gene mapping, in generation of antisense RNA and DNA, in
CC the preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, to construct hybridisation
CC probes for mapping the gene which encodes PRO and for the genetic
CC analysis of individuals with genetic disorders, in gene therapy, for
CC chromosome identification, as a chromosome marker and for generating
CC probes for PCR, Northern analysis, Southern analysis and Western
CC analysis. This sequence represents a human PRO polypeptide of the
CC invention
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 30

```
ABU81644
ID   ABU81644 standard; protein; 117 AA.
XX
AC   ABU81644;
XX
DT   24-JUN-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; gene therapy; PRO; PRO943;
KW   PRO183; PRO184; PRO185; PRO331; PRO1133; PRO363; PRO5723; PRO1387;
KW   PRO1114; PRO3301; PRO9940; PRO1181; PRO7170; PRO361; PRO846;
KW   bioactive molecule; toxin; radiolabel; antibody; cell death; cancer;
KW   autoimmune disease; chromosome mapping; gene mapping; transgenic animal;
KW   knockout animal; septic shock.
XX
OS   Homo sapiens.
XX
PN   US2002177164-A1.
XX
PD   28-NOV-2002.
XX
PF   20-NOV-2001; 2001US-00989293.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2003-328481/31.
DR   N-PSDB; ACA67937.
XX
PT   New secreted and transmembrane polypeptide, useful for modulating
PT   biological activity of cell expressing the polypeptide, for identifying
PT   agonists or antagonists of polypeptide, and as molecular weight markers.
XX
PS   Claim 12; Fig 186; 654pp; English.
XX
CC   The invention describes an isolated, secreted and transmembrane
CC   polypeptide (I), termed PRO polypeptide. (I) is useful for detecting
CC   PRO943, PRO183, PRO184, PRO185, PRO331, PRO1133, PRO363, PRO5723,
CC   PRO1387, PRO1114, PRO3301, PRO9940, PRO1181, PRO7170, PRO361 or PRO846
CC   polypeptide comprising contacting the sample with the polypeptide and
CC   determining formation of a polypeptide conjugate. (I) is also useful for
CC   linking a bioactive molecule e.g. toxin, radiolabel or antibody, to a
CC   cell expressing the above polypeptides to cause cell death. (I) is also
CC   useful as a therapeutic agent e.g. for treating cancer and autoimmune
CC   disease. PRO is useful in assays to identify other proteins or molecules
CC   involved in binding interactions. The polynucleotide (II) encoding (I) is
```

```
CC   useful in chromosome and gene mapping, for generating transgenic animals
CC   or knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, for the genetic analysis of
CC   individuals with genetic disorders, in gene therapy, for chromosome
CC   identification, and as a chromosome marker. An anti-(I)-antibody is
CC   useful in diagnostic assays for PRO, e.g. detecting its expression in
CC   specific cells, tissues or serum, for affinity purification of PRO, and
CC   for treating septic shock. This is the amino acid sequence of a novel
CC   human secreted and transmembrane PRO polypeptide
XX
SQ   Sequence 117 AA;

  Query Match           100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity  100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 31
ABU88583
ID   ABU88583 standard; protein; 117 AA.
XX
AC   ABU88583;
XX
DT   11-AUG-2003  (first entry)
XX
DE   Human secreted and transmembrane polypeptide PRO1066.
XX
KW   Human; gene therapy; cancer; retinal disorder; wound healing;
KW   kidney disorder.
XX
OS   Homo sapiens.
XX
PN   US2002197615-A1.
XX
PD   26-DEC-2002.
XX
PF   16-NOV-2001; 2001US-00991181.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
```

```
PI   Zhang Z;
XX
DR   WPI; 2003-370792/35.
DR   N-PSDB; ACA88386.
XX
PT   New secreted and transmembrane nucleic acids and polypeptides, designated
PT   as PRO, useful for the preparation of a medicament for treating a
PT   condition that is responsive to the PRO polypeptide. e.g., cancer.
XX
PS   Claim 12; Fig 186; 647pp; English.
XX
CC   The invention relates to an isolated nucleic acid encoding a PRO
CC   polypeptide. The polypeptide, agonist, antagonist and antibody are useful
CC   for the preparation of a medicament for treating a condition that is
CC   responsive to the PRO polypeptide. The nucleotide sequence is useful in
CC   molecular biology including being used as hybridisation probes, in
CC   chromosome and gene mapping and in the generation of anti-sense RNA and
CC   DNA. The PRO polypeptides can also be used in the treatment of e.g.
CC   cancer, retinal disorders, wound healing and kidney disorders. The
CC   present sequence represents the amino acid sequence of a human secreted
CC   and transmembrane PRO polypeptide of the present invention. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification but was obtained in electronic format directly from USPTO
CC   at seqdata.uspto.gov/sequence.html?DocID=20020197615
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 32
ABO34097
ID   ABO34097 standard; protein; 117 AA.
XX
AC   ABO34097;
XX
DT   19-SEP-2003  (first entry)
XX
DE   Human PRO1066 polypeptide.
XX
KW   Human; PRO polypeptide; secreted protein; transmembrane protein;
KW   biosensor; bioreactor; tumour; cancer; diabetes; ALS; ulcer;
KW   rheumatoid arthritis; amyotrophic lateral sclerosis; cytostatic;
KW   antidiabetic; antiarthritic; antirheumatic; antiulcer.
XX
OS   Homo sapiens.
XX
PN   US2003017981-A1.
XX
PD   23-JAN-2003.
XX
PF   20-NOV-2001; 2001US-00989728.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091633P.
PR   07-JUL-1998;   98US-0091982P.
```

```
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
PR   24-AUG-1998;   98US-0097661P.
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   07-SEP-2000; 2000US-0230978P.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 33
ADA45961
ID   ADA45961 standard; protein; 117 AA.
XX
AC   ADA45961;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003022328-A1.
XX
PD   30-JAN-2003.
XX
PF   16-APR-2002; 2002US-00123904.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
```

```
PR   17-SEP-1998;    98WO-US019437.
PR   07-OCT-1998;    98WO-US021141.
PR   29-OCT-1998;    98WO-US022991.
PR   29-OCT-1998;    98WO-US022992.
PR   20-NOV-1998;    98WO-US024855.
PR   01-DEC-1998;    98WO-US025108.
PR   05-JAN-1999;    99WO-US000106.
PR   08-MAR-1999;    99WO-US005028.
PR   10-MAR-1999;    99WO-US005190.
PR   20-APR-1999;    99WO-US008615.
PR   14-MAY-1999;    99WO-US010733.
PR   02-JUN-1999;    99WO-US012252.
PR   01-SEP-1999;    99WO-US020111.
PR   08-SEP-1999;    99WO-US020594.
PR   13-SEP-1999;    99WO-US020944.
PR   15-SEP-1999;    99WO-US021090.
PR   15-SEP-1999;    99WO-US021547.
PR   05-OCT-1999;    99WO-US023089.
PR   29-NOV-1999;    99WO-US028214.
PR   30-NOV-1999;    99WO-US028313.
PR   30-NOV-1999;    99WO-US028409.
PR   01-DEC-1999;    99WO-US028301.
PR   01-DEC-1999;    99WO-US028634.
PR   02-DEC-1999;    99WO-US028551.
PR   02-DEC-1999;    99WO-US028564.
PR   02-DEC-1999;    99WO-US028565.
PR   16-DEC-1999;    99WO-US030095.
PR   20-DEC-1999;    99WO-US030911.
PR   20-DEC-1999;    99WO-US030999.
PR   22-DEC-1999;    99WO-US030720.
PR   30-DEC-1999;    99WO-US031243.
PR   30-DEC-1999;    99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-584997/55.
DR   N-PSDB; ADA45960.
XX
PT   Novel secreted and transmembrane polypeptide for modulating biological
PT   activity of cell expressing the polypeptide, identifying agonists or
PT   antagonists of polypeptide, and as molecular weight markers.
XX
PS   Claim 12; Fig 442; 659pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
```

```
Qy          61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 34
ADA76392
ID ADA76392 standard; protein; 117 AA.
XX
AC ADA76392;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073212-A1.
XX
PD 17-APR-2003.
XX
PF 16-APR-2002; 2002US-00123903.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-687639/65.
DR N-PSDB; ADA76391.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.

```
XX
PS   Claim 12; Fig 442; 659pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 35
ADA19042
ID   ADA19042 standard; protein; 117 AA.
XX
AC   ADA19042;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW   colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW   glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW   cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW   factor VIIA; endothelial cell.
XX
OS   Homo sapiens.
XX
PN   US2003054517-A1.
XX
PD   20-MAR-2003.
XX
PF   08-MAY-2002; 2002US-00141755.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
```

```
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-521854/49.
DR   N-PSDB; ADA19041.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumors.
XX
PS   Claim 12; Fig 442; 660pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,
CC   prostate, rectal, cervical and liver tumours). The polynucleotides are
CC   useful in molecular biology, including uses as hybridisation probes, in
CC   chromosome and gene mapping, in generating antisense RNA and DNA and in
CC   gene therapy. The polynucleotides may also be used in preparing PRO
CC   polypeptides by recombinant techniques and in generating either
CC   transgenic animals or knock-out animals which are useful in the
CC   development and screening of therapeutically useful reagents. The PRO
CC   polypeptides or antibodies are used in preparing a medicament for
CC   treating a condition responsive to the polypeptides or antibodies, such
CC   as tumours, for modulating the uptake of glucose or FFA by adipocyte
CC   cells, for stimulating the proliferation of or gene expression in
CC   pericyte cells, for stimulating the release of proteoglycans from
CC   cartilage, for stimulating the proliferation of inner ear utricular
CC   supporting cells, for stimulating the release of cytokines from PBMC
CC   cells, for inhibiting the binding of A-peptide to factor VIIA, for
CC   inhibiting the differentiation of adipocyte cells and for stimulating the
CC   proliferation of endothelial cells. This sequence represents a human PRO
CC   polypeptide of the invention. Note: The sequence data for this patent is
CC   also available in electronic format from USPTO at
CC   seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 36
ADA61665
ID   ADA61665 standard; protein; 117 AA.
XX
AC   ADA61665;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Homo sapiens.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Novel.
OS   human.
OS   secreted.
OS   and.
OS   transmembrane.
OS   protein.
OS   PRO1066.
XX
PN   US2003049816-A1.
XX
PD   13-MAR-2003.
XX
PF   15-APR-2002; 2002US-00123262.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
```

PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695892/66.
DR N-PSDB; ADA61664.
XX
PT New PRO nucleic acid and encode polypeptides, are useful for
PT manufacturing a medicament for diagnosing or treating cancer.
XX
PS Claim 12; Fig 442; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 37
ADB19450
ID ADB19450 standard; protein; 117 AA.
XX
AC ADB19450;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;

```
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine releas.
XX
OS   Homo sapiens.
XX
PN   US2003068796-A1.
XX
PD   10-APR-2003.
XX
PF   15-APR-2002; 2002US-00123261.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-695927/66.
DR   N-PSDB; ADB19449.
XX
PT   Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT   the release of tumor necrosis factor alpha and detecting the presence of
PT   a tumor in a mammal.
XX
PS   Claim 12; Fig 442; 660pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyt
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

```
RESULT 38
ADB27991
ID   ADB27991 standard; protein; 117 AA.
XX
AC   ADB27991;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082704-A1.
XX
PD   01-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131819.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-765415/72.
DR   N-PSDB; ADB27990.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 39
ADA86470
ID   ADA86470 standard; protein; 117 AA.
XX
AC   ADA86470;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082711-A1.
XX
PD   01-MAY-2003.
XX
PF   16-MAY-2002; 2002US-00147508.
XX
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUN-1999;   99WO-US012252.
PR   07-JUL-1999;   99US-0143048P.
PR   25-AUG-1999;   99US-00380137.
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786914/74.
DR   N-PSDB; ADA86469.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
```

CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 40
ADB16034
ID ADB16034 standard; protein; 117 AA.
XX
AC ADB16034;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087350-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127821.
XX
PR 04-AUG-1998; 98US-0095301P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786941/74.
DR N-PSDB; ADB16033.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 41
ADA37779

```
ID   ADA37779 standard; protein; 117 AA.
XX
AC   ADA37779;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1066.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   c-fos induction; adipocyte cell; chondrocyte differentiation;
KW   pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW   cancer; human; colon cancer; lung cancer; breast cancer;
KW   rod photoreceptor cell.
XX
OS   Homo sapiens.
XX
PN   US2003008297-A1.
XX
PD   09-JAN-2003.
XX
PF   15-NOV-2001; 2001US-00997653.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2003-531419/50.
DR   N-PSDB; ADA37778.
XX
PT   New isolated PRO183, PRO184, PRO361 or PRO846 nucleic acid and secreted
PT   transmembrane polypeptides, useful as targets for the diagnosis and
PT   treatment of cancers, such as lung and breast cancers.
XX
PS   Claim 12; Fig 186; 660pp; English.
XX
CC   The invention relates to an isolated nucleic acid molecule comprising the
CC   full-length coding sequence of the DNA ATCC Accession Numbers given in
CC   the specification, or comprising a sequence with at least 80% identity
CC   to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an
CC   extracellular domain of the polypeptide; or (b) any of 147 nucleotide
CC   sequences fully defined in the specification. Also included are the PRO
CC   proteins (or their extracellular domains with or without their associated
CC   extracellular domains), expression vectors, host cells, PRO chimaeric
CC   proteins, anti-PRO antibodies, methods of detecting polypeptide in a
CC   sample, methods of linking a bioactive molecule to a cell expressing a
```

```
CC   polypeptide and methods of modulating at least one biological activity of
CC   a cell expressing the polypeptide. The PRO polypeptides or
CC   polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC   bioreactors. These are useful for stimulating hypertrophy of neonatal
CC   heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC   factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC   the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC   proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC   fos in endothelial cells, modulating glucose or FFA uptake by adipocyte
CC   cells, inducing proliferation and/or re-differentiation of chondrocytes,
CC   or inducing pancreatic beta-cell precursor differentiation. In
CC   particular, these are useful for detecting or treating tumours and
CC   certain cancers (colon, lung or breast cancers) in mammals, e.g. humans,
CC   dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes
CC   may also be used in gene therapy, particularly for replacing a defective
CC   gene. The present sequence represents a PRO protein.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 42
ADA47820
ID   ADA47820 standard; protein; 117 AA.
XX
AC   ADA47820;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003073215-A1.
XX
PD   17-APR-2003.
XX
PF   07-MAY-2002; 2002US-00140925.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
```

```
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-644801/61.
DR   N-PSDB; ADA47819.
XX
PT   New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT   in gene therapy, detecting the presence of tumor in a mammal, or
PT   modulating the uptake of glucose or free fatty acid by skeletal muscle
PT   cells or adipocyte cells.
XX
PS   Claim 12; Fig 442; 659pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 43
ADA21465
ID   ADA21465 standard; protein; 117 AA.
XX
AC   ADA21465;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane polypeptide PRO1066.
XX
KW   human; tumour; cancer; colorectal cancer; gene therapy;
KW   chondrocyte differentiation; VEGF inhibition;
KW   vascular endothelial growth factor; Alzheimer's disease;
KW   Parkinson's disease; atherosclerosis; cystic fibrosis;
KW   multiple sclerosis; ovarian cancer; tissue typing.
XX
OS   Homo sapiens.
XX
PN   US2003054404-A1.
XX
PD   20-MAR-2003.
XX
PF   15-NOV-2001; 2001US-00997601.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
```

PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

```
                     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 44
ADA10252
ID   ADA10252 standard; protein; 117 AA.
XX
AC   ADA10252;
XX
DT   06-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein, PRO1066.
XX
KW   PRO; secreted protein; transmembrane protein; human; septic shock;
KW   immunogen.
XX
OS   Homo sapiens.
XX
PN   US2003059831-A1.
XX
PD   27-MAR-2003.
XX
PF   19-NOV-2001; 2001US-00989729.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
```

```
PR   24-AUG-1998;   98US-0097661P.
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   07-SEP-2000; 2000US-0230978P.
PR   08-NOV-2000; 2000WO-US030952.

  Query Match           100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity  100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

```
RESULT 45
ADA67615
ID   ADA67615 standard; protein; 117 AA.
XX
AC   ADA67615;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003068795-A1.
XX
PD   10-APR-2003.
XX
PF   15-APR-2002; 2002US-00123236.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
```

```
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-695926/66.
DR   N-PSDB; ADA67614.
XX
PT   Novel isolated PRO secreted and transmembrane polypeptides useful for
PT   stimulating the release of tumor necrosis factor-alpha from human blood
PT   and detecting the presence of a tumor in a mammal.
XX
PS   Claim 12; Fig 442; 660pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 46
ADB30622
ID   ADB30622 standard; protein; 117 AA.
XX
AC   ADB30622;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003068794-A1.
XX
```

PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123155.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-708391/67.
DR N-PSDB; ADB30621.
XX
PT New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 12; Fig 442; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 47
ADA85918
ID ADA85918 standard; protein; 117 AA.
XX
AC ADA85918;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082693-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127843.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786907/74.
DR N-PSDB; ADA85917.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 48
ADA17796
ID ADA17796 standard; protein; 117 AA.
XX
AC ADA17796;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO1066 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW transgenic; tumour; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003054987-A1.
XX
PD 20-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00990443.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.

```
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   07-SEP-2000; 2000US-0230978P.
PR   08-NOV-2000; 2000WO-US030952.

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 49
ADA97130
ID   ADA97130 standard; protein; 117 AA.
XX
AC   ADA97130;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082705-A1.
XX
PD   01-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131829.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755112/71.
DR   N-PSDB; ADA97129.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 50
ADA79434
ID   ADA79434 standard; protein; 117 AA.
XX
AC   ADA79434;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
```

KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082763-A1.
XX
PD 01-MAY-2003.
XX
PF 17-APR-2002; 2002US-00124818.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755116/71.
DR N-PSDB; ADA79433.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in detection and treatment of cancer and in modulating the uptake of
PT glucose or free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 12; Fig 442; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or

```
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 51
ADA87573
ID   ADA87573 standard; protein; 117 AA.
XX
AC   ADA87573;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087345-A1.
XX
PD   08-MAY-2003.
XX
PF   16-APR-2002; 2002US-00123907.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
```

PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786937/74.
DR N-PSDB; ADA87572.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 442; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 52
ADB16775
ID ADB16775 standard; protein; 117 AA.
XX
AC ADB16775;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087349-A1.
XX
PD 08-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125928.
XX
PR 19-JUN-1998; 98US-0089947P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 02-MAR-2000; 2000WO-US005841.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786940/74.
DR N-PSDB; ADB16774.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating

```
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 53
ADA27904
ID   ADA27904 standard; protein; 117 AA.
XX
AC   ADA27904;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1066.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   rod photoreceptor cell; c-fos induction; adipocyte cell;
KW   chondrocyte differentiation;
KW   pancreatic beta-cell precursor differentiation;
KW   cardiac insufficiency disorder; wound; cancerous tumour;
KW   retinal disorders; loss of sight; retinitis pigmentosum; kidney disorder;
KW   obesity; diabetes; hyperinsulinaemia; hypoinsulinaemia; bone disorder;
KW   cartilage disorder; sports injury; arthritis; cancer; human.
XX
OS   Homo sapiens.
XX
PN   US2003054359-A1.
XX
PD   20-MAR-2003.
XX
PF   14-NOV-2001; 2001US-00990726.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
```

PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 54
ADA91867
ID ADA91867 standard; protein; 117 AA.
XX
AC ADA91867;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082694-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127845.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786908/74.
DR N-PSDB; ADA91866.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT or a composition for treating e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 55
ADB14930
ID ADB14930 standard; protein; 117 AA.
XX
AC ADB14930;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087351-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127822.
XX
PR 17-JUN-1998; 98US-0089532P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786942/74.
DR N-PSDB; ADB14929.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 56
ADB18891
ID ADB18891 standard; protein; 117 AA.
XX
AC ADB18891;
XX
DT 20-NOV-2003 (first entry)

XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine releas.
XX
OS Homo sapiens.
XX
PN US2003073211-A1.
XX
PD 17-APR-2003.
XX
PF 15-APR-2002; 2002US-00123292.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695954/66.
DR N-PSDB; ADB18890.
XX
PT New isolated nucleic acid and encoded PRO polypeptide, are useful in the
PT diagnosis and treatment of cancer.
XX
PS Claim 12; Fig 442; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyt
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

```
Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 57
ADA94106
ID   ADA94106 standard; protein; 117 AA.
XX
AC   ADA94106;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077722-A1.
XX
PD   24-APR-2003.
XX
PF   03-MAY-2002; 2002US-00137872.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755077/71.
DR   N-PSDB; ADA94105.
XX
PT   New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT   diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT   breast, prostate, rectal, cervical and/or liver tumors.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 58
ADB20002
ID   ADB20002 standard; protein; 117 AA.
XX
AC   ADB20002;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082691-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127838.
XX
PR   17-NOV-1998;   98US-0108802P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-AUG-2000; 2000WO-US023522.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755108/71.
DR   N-PSDB; ADB20001.
```

XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 117 AA;

```
  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 59
ADB13314
ID ADB13314 standard; protein; 117 AA.
XX
AC ADB13314;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.
XX
OS Homo sapiens.

XX
PN US2003082710-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147484.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786913/74.
DR N-PSDB; ADB13313.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide, preparing a composition for treating e.g., tumor, or for tissue typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

```
  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

```
RESULT 60
ABO43369
ID   ABO43369 standard; protein; 117 AA.
XX
AC   ABO43369;
XX
DT   26-SEP-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO; gene therapy;
KW   chromosome identification; tissue typing.
XX
OS   Homo sapiens.
XX
PN   US2003044945-A1.
XX
PD   06-MAR-2003.
XX
PF   10-MAY-2002; 2002US-00142419.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-492275/46.
DR   N-PSDB; ACD98644.
XX
PT   New transmembrane polypeptides and nucleic acids encoding the
PT   polypeptides, useful in gene therapy, in chromosome identification, as
PT   chromosome markers, or in generating probes.
XX
PS   Claim 12; Fig 442; 660pp; English.
XX
CC   The invention describes an isolated nucleic acid encoding a PRO (secreted
CC   and transmembrane) polypeptide. Nucleic acids which encode PRO can be
CC   used to generate either transgenic animals or knock-out animals useful in
CC   developing and screening of therapeutically useful reagents. The nucleic
CC   acids may also be used in gene therapy, in chromosome identification, as
CC   chromosome markers, or in generating probes. The PRO polypeptides are
CC   useful as molecular markers for protein electrophoresis, and the isolated
CC   nucleic acids may be used for recombinantly expressing those markers. The
CC   PRO polypeptides and nucleic acids may also be used in tissue typing.
```

```
CC   Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. This is the amino acid sequence of a novel human secreted and
CC   transmembrane PRO polypeptide
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 61
ADA94484
ID   ADA94484 standard; protein; 117 AA.
XX
AC   ADA94484;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1066.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   c-fos induction; adipocyte cell; chondrocyte differentiation;
KW   pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW   cancer; human; colon cancer; lung cancer; breast cancer;
KW   rod photoreceptor cell.
XX
OS   Homo sapiens.
XX
PN   US2003059832-A1.
XX
PD   27-MAR-2003.
XX
PF   15-NOV-2001; 2001US-00997349.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
```

```
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
PR   24-AUG-1998;   98US-0097661P.
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.

  Query Match            100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity  100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 62
ADA74568
ID   ADA74568 standard; protein; 117 AA.
XX
AC   ADA74568;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003068798-A1.
XX
PD   10-APR-2003.
XX
PF   07-MAY-2002; 2002US-00140928.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
```

```
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-625490/59.
DR   N-PSDB; ADA74567.
XX
PT   Novel secreted and transmembrane PRO polypeptides and polynucleotides
PT   encoding them, useful for treating bone disorders, arthritis, heart
PT   attack, injuries, tumors, and stimulating release of Tumor Necrosis
PT   Factor-alpha from human blood.
XX
PS   Claim 12; Fig 442; 659pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 63
ADB24801
ID   ADB24801 standard; protein; 117 AA.
XX
AC   ADB24801;
XX
DT   20-NOV-2003  (first entry)
XX
```

DE Human PRO polypeptide SEQ ID NO 442.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077713-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127839.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755068/71.
DR N-PSDB; ADB24800.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

```
  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 64
ADA82325
ID ADA82325 standard; protein; 117 AA.
XX
AC ADA82325;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082701-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128686.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755110/71.
DR N-PSDB; ADA82324.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

```
  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 65
ADA75288
ID ADA75288 standard; protein; 117 AA.
XX
AC ADA75288;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073216-A1.
XX
PD 17-APR-2003.
XX
PF 30-MAY-2002; 2002US-00160498.

XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-765392/72.
DR N-PSDB; ADA75287.
XX
PT New secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha in human blood and detecting
PT the presence of tumor in a mammal.
XX
PS Claim 12; Fig 442; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalaesaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 66
ADA85366
ID ADA85366 standard; protein; 117 AA.
XX
AC ADA85366;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082695-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127846.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786909/74.
DR N-PSDB; ADA85365.
XX
PT New nucleic acid encoding a PRO polypeptide, useful for preparing a
PT composition for treating e.g. tumor by gene therapy, or for tissue
PT typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,

```
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 67
ADA84814
ID   ADA84814 standard; protein; 117 AA.
XX
AC   ADA84814;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082708-A1.
XX
PD   01-MAY-2003.
XX
PF   15-MAY-2002; 2002US-00146729.
XX
PR   05-JUN-2000; 2000US-0209832P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786911/74.
DR   N-PSDB; ADA84813.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g. tumor or for tissue typing.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 68
ADB30070
ID   ADB30070 standard; protein; 117 AA.
XX
AC   ADB30070;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
```

KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073214-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124822.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-720081/68.
DR N-PSDB; ADB30069.
XX
PT Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX
PS Claim 12; Fig 442; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

```
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 69
ADA80598
ID   ADA80598 standard; protein; 117 AA.
XX
AC   ADA80598;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082761-A1.
XX
PD   01-MAY-2003.
XX
PF   12-APR-2002; 2002US-00121061.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
```

```
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-755115/71.
DR   N-PSDB; ADA80597.
XX
PT   New PRO polypeptides useful for treating diabetes, hyper- or hypo-
PT   insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,
PT   various coagulation disorders and tumors.
XX
PS   Claim 12; Fig 442; 638pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 70
ADA75840
ID   ADA75840 standard; protein; 117 AA.
XX
AC   ADA75840;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082703-A1.
XX
PD   01-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128691.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zharg Z;
XX
DR   WPI; 2003-765414/72.
DR   N-PSDB; ADA75839.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
```

```
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 71
ADA38709
ID   ADA38709 standard; protein; 117 AA.
XX
AC   ADA38709;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1066.
XX
KW   PRO; secreted protein; transmembrane protein; gene therapy; tumour;
KW   cancer; human; colon cancer; lung cancer; breast cancer.
XX
OS   Homo sapiens.
XX
PN   US2003059780-A1.
XX
PD   27-MAR-2003.
XX
PF   14-NOV-2001; 2001US-00991854.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
```

PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 72
ADA47065
ID ADA47065 standard; protein; 117 AA.
XX
AC ADA47065;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073210-A1.
XX
PD 17-APR-2003.
XX
PF 11-APR-2002; 2002US-00121045.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-644800/61.
DR N-PSDB; ADA47064.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 442; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 73
ADB25361
ID ADB25361 standard; protein; 117 AA.
XX

AC ADB25361;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 442.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077715-A1.
XX
PD 24-APR-2003.
XX
PF 23-APR-2002; 2002US-00128693.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755070/71.
DR N-PSDB; ADB25360.
XX
PT New isolated, secreted and transmembrane PRO nucleic acids, useful for
PT the diagnosis, prevention and/or treatment of tumors, such as lung,
PT colon, breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 74
ADA93537
ID ADA93537 standard; protein; 117 AA.
XX
AC ADA93537;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077721-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131837.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755076/71.
DR N-PSDB; ADA93536.
XX
PT New PRO nucleic acid, useful for recombinantly producing a PRO
PT polypeptide and for manufacturing a medicament for diagnosing or treating
PT tumor.
XX
PS Claim 12; Fig 442; 637pp; English.
XX

```
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 75
ADB26887
ID   ADB26887 standard; protein; 117 AA.
XX
AC   ADB26887;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003092147-A1.
XX
PD   15-MAY-2003.
XX
PF   11-APR-2002; 2002US-00121051.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
```

PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777249/73.
DR N-PSDB; ADB26886.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
PS Claim 12; Fig 442; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 76
ADB31174
ID ADB31174 standard; protein; 117 AA.
XX
AC ADB31174;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003096386-A1.
XX
PD 22-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121042.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786990/74.
DR N-PSDB; ADB31173.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
PS Claim 12; Fig 442; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 77
ADA92830
ID ADA92830 standard; protein; 117 AA.

XX
AC ADA92830;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1066.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003060407-A1.
XX
PD 27-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00990440.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.

```
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.

  Query Match           100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity  100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 78
ADA61102
ID   ADA61102 standard; protein; 117 AA.
XX
AC   ADA61102;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Homo sapiens.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Novel.
OS   human.
OS   secreted.
OS   and.
OS   transmembrane.
OS   protein.
OS   PRO1066.
XX
PN   US2003049817-A1.
XX
PD   13-MAR-2003.
XX
PF   10-MAY-2002; 2002US-00142423.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
```

PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PR 10-MAR-2009; 2000WO-US006319.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695893/66.
DR N-PSDB; ADA61101.
XX
PT New secreted and transmembrane PRO polypeptide and nucleic acid, useful
PT for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 442; 658pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 79
ADB24249
ID ADB24249 standard; protein; 117 AA.
XX
AC ADB24249;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 442.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077714-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127901.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.

```
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755069/71.
DR   N-PSDB; ADB24248.
XX
PT   New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT   acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT   such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT   tumors.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 80
ADA96578
ID   ADA96578 standard; protein; 117 AA.
XX
AC   ADA96578;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082690-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127837.
XX
PR   01-SEP-1998;   98US-0098750P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755107/71.
DR   N-PSDB; ADA96577.
XX
PT   PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT   tumor or for tissue typing.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
```

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 81
ADA81150
ID ADA81150 standard; protein; 117 AA.
XX
AC ADA81150;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082702-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128690.
XX
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755111/71.
DR N-PSDB; ADA81149.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 82
ADA96026
ID ADA96026 standard; protein; 117 AA.
XX
AC ADA96026;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082759-A1.
XX
PD 01-MAY-2003.

XX
PF 11-APR-2002; 2002US-00121040.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755114/71.
DR N-PSDB; ADA96025.
XX
PT New isolated PRO polypeptides, useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders and tumors.
XX
PS Claim 12; Fig 442; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-

```
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 83
ADB26335
ID   ADB26335 standard; protein; 117 AA.
XX
AC   ADB26335;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082760-A1.
XX
PD   01-MAY-2003.
XX
PF   12-APR-2002; 2002US-00121056.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
```

```
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-777204/73.
DR   N-PSDB; ADB26334.
XX
PT   New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT   in gene therapy, detecting the presence of tumor in a mammal, or
PT   modulating the uptake of glucose or free fatty acid by skeletal muscle
PT   cells or adipocyte cells.
XX
PS   Claim 12; Fig 442; 659pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 6;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 84
ADB21820
ID   ADB21820 standard; protein; 117 AA.
XX
AC   ADB21820;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082765-A1.
XX
PD   01-MAY-2003.
XX
PF   17-MAY-2002; 2002US-00147492.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000;  2000WO-US000219.
PR   06-JAN-2000;  2000WO-US000277.
PR   06-JAN-2000;  2000WO-US000376.
PR   11-FEB-2000;  2000WO-US003565.
PR   18-FEB-2000;  2000WO-US004341.
PR   18-FEB-2000;  2000WO-US004342.
PR   22-FEB-2000;  2000WO-US004414.
PR   24-FEB-2000;  2000WO-US004914.
PR   24-FEB-2000;  2000WO-US005004.
```

PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786920/74.
DR N-PSDB; ADB21819.
XX
PT New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 12; Fig 442; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 6; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 85
ADA77599
ID ADA77599 standard; protein; 117 AA.
XX
AC ADA77599;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068797-A1.
XX
PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140921.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625489/59.
DR N-PSDB; ADA77598.
XX
PT Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801
PT and PRO1114, useful in the preparation of a medicament for treating a
PT condition responsive to PRO polypeptide, and as therapeutic agents e.g.
PT vaccines.
XX
PS Claim 12; Fig 442; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 7; Length 117;

```
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 86
ADB18339
ID   ADB18339 standard; protein; 117 AA.
XX
AC   ADB18339;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077710-A1.
XX
PD   24-APR-2003.
XX
PF   22-APR-2002; 2002US-00127825.
XX
PR   22-OCT-1998;   98US-0105169P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   30-NOV-1999;   99WO-US028313.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755065/71.
DR   N-PSDB; ADB18338.
XX
PT   New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT   in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT   in tissue typing, and in identifying chromosomes.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 7;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 87
ADA87022
ID   ADA87022 standard; protein; 117 AA.
XX
AC   ADA87022;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082709-A1.
XX
PD   01-MAY-2003.
XX
PF   15-MAY-2002; 2002US-00146791.
XX
PR   17-AUG-1998;   98US-0096895P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
```

XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786912/74.
DR N-PSDB; ADA87021.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT for preparing a composition for treating e.g., tumor, or for tissue
PT typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 88
ADA88125
ID ADA88125 standard; protein; 117 AA.
XX
AC ADA88125;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082700-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128684.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786910/74.
DR N-PSDB; ADA88124.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
```

```
Qy          61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 89
ADA46513
ID   ADA46513 standard; protein; 117 AA.
XX
AC   ADA46513;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003054516-A1.
XX
PD   20-MAR-2003.
XX
PF   12-APR-2002; 2002US-00121050.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000;   2000WO-US000219.
PR   06-JAN-2000;   2000WO-US000277.
PR   06-JAN-2000;   2000WO-US000376.
PR   11-FEB-2000;   2000WO-US003565.
PR   18-FEB-2000;   2000WO-US004341.
PR   18-FEB-2000;   2000WO-US004342.
PR   22-FEB-2000;   2000WO-US004414.
PR   24-FEB-2000;   2000WO-US004914.
PR   24-FEB-2000;   2000WO-US005004.
PR   01-MAR-2000;   2000WO-US005601.
PR   02-MAR-2000;   2000WO-US005746.
PR   02-MAR-2000;   2000WO-US005841.
PR   10-MAR-2000;   2000WO-US006319.
PR   15-MAR-2000;   2000WO-US006884.
PR   20-MAR-2000;   2000WO-US007377.
PR   21-MAR-2000;   2000WO-US007532.
PR   30-MAR-2000;   2000WO-US008439.
PR   17-MAY-2000;   2000WO-US013705.
PR   22-MAY-2000;   2000WO-US014042.
PR   30-MAY-2000;   2000WO-US014941.
PR   02-JUN-2000;   2000WO-US015264.
PR   28-JUL-2000;   2000WO-US020710.
PR   11-AUG-2000;   2000WO-US022031.
PR   23-AUG-2000;   2000WO-US023522.
PR   24-AUG-2000;   2000WO-US023328.
PR   08-NOV-2000;   2000WO-US030952.
PR   10-NOV-2000;   2000WO-US030873.
PR   01-DEC-2000;   2000WO-US032678.
PR   20-DEC-2000;   2000US-00747259.
PR   20-DEC-2000;   2000WO-US034956.
PR   28-FEB-2001;   2001US-00796498.
PR   28-FEB-2001;   2001WO-US006520.
PR   01-MAR-2001;   2001WO-US006666.
PR   09-MAR-2001;   2001US-00802706.
PR   14-MAR-2001;   2001US-00808689.
PR   22-MAR-2001;   2001US-00816744.
PR   05-APR-2001;   2001US-00828366.
PR   10-MAY-2001;   2001US-00854208.
PR   10-MAY-2001;   2001US-00854280.
PR   18-MAY-2001;   2001US-00860216.
PR   25-MAY-2001;   2001US-00866028.
PR   25-MAY-2001;   2001US-00866034.
PR   25-MAY-2001;   2001WO-US017092.
PR   01-JUN-2001;   2001US-00872035.
PR   01-JUN-2001;   2001WO-US017800.
PR   05-JUN-2001;   2001US-00874503.
PR   14-JUN-2001;   2001US-00882636.
PR   19-JUN-2001;   2001US-00886342.
PR   20-JUN-2001;   2001WO-US019692.
PR   21-JUN-2001;   2001US-00887879.
PR   22-JUN-2001;   2001WO-US020116.
PR   29-JUN-2001;   2001WO-US021066.
PR   09-JUL-2001;   2001WO-US021735.
PR   18-JUL-2001;   2001US-00908827.
PR   06-AUG-2001;   2001US-00924419.
PR   09-AUG-2001;   2001US-00927796.
PR   16-AUG-2001;   2001US-00931836.
PR   19-DEC-2001;   2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-521853/49.
DR   N-PSDB; ADA46512.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor.
XX
PS   Claim 12; Fig 442; 200pp; English.
XX
```

CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 90
ADB28543
ID ADB28543 standard; protein; 117 AA.
XX
AC ADB28543;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #221.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082699-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127851.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777202/73.
DR N-PSDB; ADB28542.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 442; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
Db 1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
Db 61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 91

```
ADB29095
ID   ADB29095 standard; protein; 117 AA.
XX
AC   ADB29095;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082706-A1.
XX
PD   01-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131836.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforgre L,  Desnoyers L,  Filvaroff E;
PI   Gao W,  Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-777203/73.
DR   N-PSDB; ADB29094.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 442; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 7;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 92
ABO53183
ID   ABO53183 standard; protein; 117 AA.
XX
AC   ABO53183;
XX
DT   14-OCT-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1066.
XX
KW   Human; secreted protein; transmembrane protein; PRO;
KW   adrenal cortical capillary endothelial cell; angiogenesis; wound healing;
KW   diabetes; obesity; hyper-insulinaemia; hypo-insulinaemia;
KW   chondrocyte redifferentiation; bone disorder; cartilage disorder;
KW   sports injury; arthritis; kidney mesangial cell proliferation;
KW   kidney disorder; Berger disease; neuropathy; coeliac disease;
KW   dermatitis herpetiformis; Crohn's disease; tumour; cancer.
XX
OS   Homo sapiens.
XX
PN   US2003044806-A1.
XX
PD   06-MAR-2003.
XX
PF   15-NOV-2001; 2001US-00998156.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
```

PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.

```
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.

  Query Match             100.0%;  Score 611;  DB 7;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 93
ADA77047
ID   ADA77047 standard; protein; 117 AA.
XX
AC   ADA77047;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003059909-A1.
XX
PD   27-MAR-2003.
XX
PF   10-MAY-2002; 2002US-00143032.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
```

PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-540684/51.
DR N-PSDB; ADA77046.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 442; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 117 AA;

Query Match 100.0%; Score 611; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 94
ADA22391
ID ADA22391 standard; protein; 117 AA.
XX
AC ADA22391;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane polypeptide PRO1066.
XX
KW human; tumour; cancer; colorectal cancer; gene therapy;
KW chondrocyte differentiation; VEGF inhibition;
KW vascular endothelial growth factor; Alzheimer's disease;
KW Parkinson's disease; atherosclerosis; cystic fibrosis;
KW multiple sclerosis; ovarian cancer; tissue typing.
XX
OS Homo sapiens.
XX
PN US2003040473-A1.
XX
PD 27-FEB-2003.
XX
PF 19-NOV-2001; 2001US-00989726.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.

```
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
PR   24-AUG-1998;   98US-0097661P.
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.

  Query Match             100.0%;  Score 611;  DB 7;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117

RESULT 95
ADA88677
ID   ADA88677 standard; protein; 117 AA.
XX
AC   ADA88677;
XX
DT   20-NOV-2003  (first entry)
XX
```

DE Novel human secreted and transmembrane protein PRO1066.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003073213-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124819.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743816/70.
DR N-PSDB; ADA88676.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 12; Fig 442; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

```
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 7;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 96
ADA97682
ID   ADA97682 standard; protein; 117 AA.
XX
AC   ADA97682;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082686-A1.
XX
PD   01-MAY-2003.
XX
PF   19-APR-2002; 2002US-00125926.
XX
PR   05-JUN-2000; 2000US-0209832P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755106/71.
DR   N-PSDB; ADA97681.
XX
PT   Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT   PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy.
XX
PS   Claim 12; Fig 442; 666pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 117 AA;

  Query Match             100.0%;  Score 611;  DB 7;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 97
ADB27439
ID   ADB27439 standard; protein; 117 AA.
XX
AC   ADB27439;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #221.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
```

KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003022239-A1.
XX
PD 30-JAN-2003.
XX
PF 12-APR-2002; 2002US-00121049.
XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.

```
PR   07-OCT-1998;   98US-0103315P.
PR   07-OCT-1998;   98US-0103328P.
PR   07-OCT-1998;   98WO-US021141.
PR   13-OCT-1998;   98US-0104080P.
PR   20-OCT-1998;   98US-0104987P.
PR   22-OCT-1998;   98US-0105169P.
PR   28-OCT-1998;   98US-0106030P.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   30-OCT-1998;   98US-0106464P.
PR   03-NOV-1998;   98US-0106856P.
PR   03-NOV-1998;   98US-0106934P.
PR   10-NOV-1998;   98US-0107783P.
PR   17-NOV-1998;   98US-0108775P.
PR   17-NOV-1998;   98US-0108801P.
PR   17-NOV-1998;   98US-0108802P.
PR   17-NOV-1998;   98US-0108925P.
PR   20-NOV-1998;   98US-0109304P.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   15-DEC-1998;   98US-0112743P.
PR   16-DEC-1998;   98US-0112850P.
PR   22-DEC-1998;   98US-0113296P.
PR   22-DEC-1998;   98US-0113299P.
PR   22-DEC-1998;   98US-0113300P.
PR   22-DEC-1998;   98US-0113313P.
PR   22-DEC-1998;   98US-0113314P.
PR   22-DEC-1998;   98US-0113315P.
PR   22-DEC-1998;   98US-0113510P.
PR   22-DEC-1998;   98US-0113511P.
PR   23-DEC-1998;   98US-0113605P.
PR   23-DEC-1998;   98US-0113621P.
PR   05-JAN-1999;   99WO-US000106.
PR   12-JAN-1999;   99US-0115549P.
PR   12-JAN-1999;   99US-0115557P.
PR   12-JAN-1999;   99US-0115560P.
PR   12-JAN-1999;   99US-0115562P.
PR   12-JAN-1999;   99US-0115564P.
PR   12-JAN-1999;   99US-0115630P.
PR   12-JAN-1999;   99US-0115705P.
PR   12-JAN-1999;   99US-0115733P.

  Query Match           100.0%;  Score 611;  DB 7;  Length 117;
  Best Local Similarity  100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 98
ADB22372
ID   ADB22372 standard; protein; 117 AA.
XX
AC   ADB22372;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1066.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087344-A1.
XX
PD   08-MAY-2003.
XX
PF   16-APR-2002; 2002US-00123905.
XX
PR   18-JUN-1997;   97US-0049911P.
PR   26-AUG-1997;   97US-0056974P.
PR   17-SEP-1997;   97US-0059113P.
PR   17-SEP-1997;   97US-0059115P.
PR   17-SEP-1997;   97US-0059117P.
PR   17-SEP-1997;   97US-0059122P.
PR   17-SEP-1997;   97US-0059184P.
PR   18-SEP-1997;   97US-0059263P.
PR   19-SEP-1997;   97US-0059352P.
PR   19-SEP-1997;   97US-0059588P.
PR   24-SEP-1997;   97US-0059836P.
PR   17-OCT-1997;   97US-0062250P.
PR   17-OCT-1997;   97US-0062285P.
PR   17-OCT-1997;   97US-0062287P.
PR   17-OCT-1997;   97US-0063755P.
PR   24-OCT-1997;   97US-0062814P.
PR   24-OCT-1997;   97US-0062816P.
PR   24-OCT-1997;   97US-0063045P.
PR   24-OCT-1997;   97US-0063082P.
PR   24-OCT-1997;   97US-0063127P.
PR   27-OCT-1997;   97US-0063327P.
PR   27-OCT-1997;   97US-0063329P.
PR   28-OCT-1997;   97US-0063550P.
PR   28-OCT-1997;   97US-0063561P.
PR   29-OCT-1997;   97US-0063704P.
PR   29-OCT-1997;   97US-0063733P.
PR   29-OCT-1997;   97US-0063735P.
PR   29-OCT-1997;   97US-0063738P.
PR   03-NOV-1997;   97US-0064248P.
PR   07-NOV-1997;   97US-0064809P.
PR   12-NOV-1997;   97US-0065186P.
PR   17-NOV-1997;   97US-0065846P.
PR   21-NOV-1997;   97US-0066364P.
PR   24-NOV-1997;   97US-0066453P.
PR   24-NOV-1997;   97US-0066511P.
PR   24-NOV-1997;   97US-0066770P.
PR   11-DEC-1997;   97US-0069212P.
PR   11-DEC-1997;   97US-0069278P.
PR   11-DEC-1997;   97US-0069334P.
PR   16-DEC-1997;   97US-0069694P.
PR   23-JAN-1998;   98US-0072320P.
PR   04-FEB-1998;   98US-0073612P.
PR   09-FEB-1998;   98US-0074086P.
PR   09-FEB-1998;   98US-0074092P.
PR   12-MAR-1998;   98US-0077791P.
PR   20-MAR-1998;   98US-0078910P.
PR   25-MAR-1998;   98US-0079294P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079728P.
PR   31-MAR-1998;   98US-0080165P.
PR   09-APR-1998;   98US-0081229P.
PR   14-APR-1998;   98US-0081695P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081818P.
PR   24-APR-1998;   98US-0082999P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083545P.
PR   07-MAY-1998;   98US-0084600P.
PR   07-MAY-1998;   98US-0084627P.
PR   07-MAY-1998;   98US-0084637P.
PR   12-MAY-1998;   98US-0085149P.
PR   13-MAY-1998;   98US-0085323P.
PR   13-MAY-1998;   98US-0085338P.
PR   13-MAY-1998;   98US-0085339P.
```

PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.
PR 20-JAN-1999; 99US-0116533P.
PR 01-FEB-1999; 99US-0118210P.

Query Match 100.0%; Score 611; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 4e-59;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
```

RESULT 99
ABO22553
ID ABO22553 standard; protein; 117 AA.
XX
AC ABO22553;
XX
DT 04-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1066.
XX
KW Human; PRO; secreted protein; transmembrane protein; antidiabetic;
KW cytostatic; antirheumatic; antiarthritic; antiulcer; neuroprotective;
KW antiinflammatory; antibacterial; immunosuppressive; gene therapy;
KW diabetes; cancer; rheumatoid arthritis; ulcers;
KW amyotrophic lateral sclerosis; inflammatory condition; septic shock.
XX
OS Homo sapiens.
XX
PN US2003017982-A1.
XX
PD 23-JAN-2003.

XX
PF 16-NOV-2001; 2001US-00990441.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.

```
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.

  Query Match           100.0%;  Score 611;  DB 7;  Length 117;
  Best Local Similarity  100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


RESULT 100
ADA06557
ID   ADA06557 standard; protein; 117 AA.
XX
AC   ADA06557;
XX
DT   29-JAN-2004  (revised)
DT   06-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane PRO polypeptide #78.
XX
KW   human; tissue typing; cardiac insufficiency disorder; angiogenesis;
KW   wound healing; tumour; immune response; retinal disorder; retinal injury;
KW   sight loss; age-related macular degeneration; AMD; kidney disorder;
KW   mesangial cell function; Berger disease; nephropathy; dermatitis;
KW   herpetiform; Crohn's disease; sports injury; arthritis.
XX
OS   Homo sapiens.
XX
PN   US2003049638-A1.
XX
PD   13-MAR-2003.
XX
PF   16-NOV-2001; 2001US-00991157.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
```

```
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   13-AUG-1998;   98US-0096413P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
PR   24-AUG-1998;   98US-0097661P.
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.

  Query Match             100.0%;  Score 611;  DB 7;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 4e-59;
  Matches  117;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPE 60

Qy         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 117


Search completed: May  9, 2006, 18:28:22
Job time : 113 secs
<UL>
<LI><STRONG>pat</STRONG>
<UL>
<LI>US09718803
</UL>
<LI><STRONG>dir</STRONG>
<UL>
<LI>runat_09052006_152016_7012
</UL>
<LI><STRONG>printer</STRONG>
<UL>
<LI>0
</UL>
<LI><STRONG>html_save</STRONG>
<UL>
<LI>0
</UL>
<LI><STRONG>runat_09052006_152016_7012</STRONG>
<UL>
<LI>US-09-718-803A-2
</UL>
<LI><STRONG>save</STRONG>
<UL>
<LI>Save As
</UL>
```

</UL>
IN=/abss/ABSSWEB_spool/US09718803/runat_09052006_152016_7012/output, F=/abss/ABSSWEB_spo